Systems and methods for identifying an access port

Description

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows a perspective view of an embodiment of an access port according to the instant disclosure;

FIG. 1B shows a schematic side cross-sectional view the access port shown in FIG. 1A;

FIG. 2 shows a perspective view of an embodiment of an access port according to the instant disclosure;

FIG. 3 shows a perspective view of an access port according to the instant disclosure;

FIG. 4 shows a perspective view of an access port according to the instant disclosure;

FIG. 5 shows a perspective view of an access port according to the instant disclosure;

FIG. 6A shows a perspective view of an access port according to the instant disclosure;

FIG. 6B shows a side view of the access port shown in FIG. 6A;

FIG. 7 shows a perspective view of an access port according to the instant disclosure;

FIG. 8 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;

FIG. 9 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;

FIG. 10 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;

FIG. 11 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;

FIG. 12 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;

FIG. 13 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;

FIG. 14 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;

FIG. 15A shows a perspective view of an embodiment of an access port according to the instant disclosure;

FIG. 15B shows a top elevation view of the access port shown in FIG. 15A;

FIG. 16 shows a perspective view of an access port according to the instant disclosure;

FIG. 17 shows a perspective view of an access port according to the instant disclosure;

FIG. 18 shows a perspective view of an access port according to the instant disclosure;

FIG. 19 shows a perspective view of an access port according to the instant disclosure;

FIG. 20 shows a perspective view of an access port according to the instant disclosure;

FIG. 21 shows a perspective view of an access port according to the instant disclosure;

FIG. 22 shows a perspective view of another embodiment of an access port according to the instant disclosure;

FIG. 23 shows a top elevation view of the assembled access port shown in FIG. 22;

FIG. 24 shows a simplified representation of a transverse cross section of the access port shown in FIGS. 22 and 23;

FIGS. 25-51 show perspective views of additional embodiments of an access port;

FIG. 52 shows a bottom perspective view of an access port according to one embodiment;

FIG. 53A shows a top view of the access port shown in FIG. 52;

FIG. 53B shows a bottom view of the access port shown in FIG. 52;

FIG. 54A represents a radiographic image of the access port shown in FIG. 52 when viewed from above the access port;

FIG. 54B represents a radiographic image of the access port shown in FIG. 52 when viewed at an angle of approximately 20 degrees;

FIG. 54C represents a radiographic image of the access port shown in FIG. 52 when viewed at an angle of approximately 50 degrees;

FIG. 55 shows a cross-sectional view of the access port shown in FIG. 52;

FIGS. 56A and 56B show cross-sectional views of example embodiments of engraved features on an access port surface;

FIG. 57A shows a top perspective view of an access port according to one embodiment;

FIG. 57B shows a bottom perspective view of the access port shown in FIG. 57A;

FIG. 57C shows a bottom view of the access port shown in FIG. 57A;

FIG. 58A shows a top perspective view of another embodiment of an access port;

FIG. 58B shows a bottom perspective view of the access port shown in FIG. 58A;

FIG. 58C shows a bottom view of the access port shown in FIG. 58A;

FIG. 59A shows a side view of an embodiment of an access port;

FIG. 59B shows a bottom view of the access port shown in FIG. 59A;

FIG. 60A shows a bottom perspective view of an additional embodiment of an access port;

FIG. 60B shows a bottom view of the access port shown in FIG. 60A;

FIG. 61A shows a bottom perspective view of an additional embodiment of an access port;

FIG. 61B shows a bottom view of the access port shown in FIG. 61A;

FIG. 62A shows a bottom view of an additional embodiment of an access port;

FIG. 62B shows a side view of the access port shown in FIG. 62A;

FIG. 62C shows an end view of the access port shown in FIG. 62A;

FIG. 63A shows a bottom view of another embodiment of an access port;

FIG. 63B shows a side view of the access port shown in FIG. 63A;

FIG. 63C shows an end view of the access port shown in FIG. 63A;

FIG. 64 shows a top view of an access port according to one embodiment;

FIG. 65 shows a perspective view of an access port according to one embodiment;

FIGS. 66A-66D show various views of an access port according to one embodiment;

FIG. 67 shows a bottom perspective view of an access port according to one embodiment;

FIGS. 68A-68C show various views of a septum of an access port according to one embodiment;

FIG. 69 shows a perspective view of an access port according to one embodiment;

FIG. 70 shows a perspective view of an identifier for an access port according to one embodiment;

FIG. 71 shows a top view of an identifier for an access port according to one embodiment;

FIG. 72 shows a perspective view of a port and a catheter including an identifier according to one embodiment;

FIGS. 73A and 73B show various views of an identifier for an access port according to one embodiment;

FIGS. 74A and 74B show views of an identifier for an access port according to one embodiment; and

FIGS. 75A-75C show various views of an identifier for an access port according to one embodiment.

DETAILED DESCRIPTION

The instant disclosure relates generally to percutaneous access and, more specifically, to methods and devices associated with percutaneous access. Generally, the instant disclosure relates to an access port for subcutaneous implantation. In one embodiment, an access port may allow a physician or other medical personnel to obtain long term percutaneous access to the interior of a patient's body. Employing an access port for percutaneous access may reduce the opportunity for infection by inhibiting fluid connections (that extend into the interior of a patient's body) from the patient's skin and from the external environment. The access device allows access to the interior of the patient without requiring a needle to pierce the skin. Further, internal components, such as a catheter or a valve, may be replaced without a surgical procedure. Features or aspects of the instant disclosure may apply to any such access ports for subcutaneous access to a patient, without limitation. The access port may be injected by hand (e.g., via a syringe including a needle) for example, or may be injected and pressurized by mechanical assistance (e.g., a so-called power injectable port).

Power injectable ports may be employed in, among other processes, for example, computed tomography (“CT”) scanning processes. More particularly, a so-called “power injector” system may be employed for injecting contrast media into a peripherally inserted intravenous (IV) line. For example, such power injectors or injection systems may be commercially available from Medrad, Inc., a subsidiary of Schering AG, Germany and may be marketed under the trademark STELLANT®. Because fluid infusion procedures are often defined in terms of a desired flow rate of contrast media, such power injection systems are, in general, controllable by selecting a desired flow rate.

More specifically, the instant disclosure relates to an access port having at least one perceivable or identifiable feature for identifying the access port, wherein the identifiable feature is perceivable after the access port is implanted within a patient. For example, at least one or perhaps multiple identifiable feature(s) of an access port contemplated by the instant disclosure may be correlative to information (e.g., a manufacturer's model or design) pertaining to the access port. Thus, an identifiable feature from an access port of a particular model may be unique in relation to most if not all other identifiable features of another access port of a different models or design. Of course, the at least one identifiable feature of an access port contemplated by the instant disclosure may be further correlative with any information of interest, such as type of port, catheter type, date of manufacture, material lots, part numbers, etc. In one example, at least one identifiable feature of an access port may be correlative with the access port being power injectable. In this way, once at least one identifiable feature of an access port is observed or otherwise determined, correlation of such at least one feature of an access port may be accomplished, and information pertaining to the access port may be obtained.

In one embodiment, at least one feature may be perceived by palpation (i.e., to examine by touch), by way of other physical interaction, or by visual observation. Accordingly, a person of interest may touch or feel the access port through the skin to perceive at least one identifying characteristic thereof. In another embodiment, at least one identifiable feature may be perceived via x-ray or ultrasound imaging. In yet a further embodiment, at least one identifiable feature may be perceived through magnetic, light, or radio energy interaction or communication with the access port.

Turning to the embodiment wherein at least one feature may be perceived through palpation, other physical interaction, or visual observation, a topography or exterior surface feature of an access port contemplated by the instant disclosure may be configured for perception. For example, referring to FIGS. 1A and 1B, an exemplary access port 10 contemplated by the instant disclosure is shown. FIGS. 1A and 1B show a perspective view and a schematic side cross-sectional view, respectively, of an access port 10 for allowing percutaneous or otherwise internal access to a patient's body. Access port 10 includes a housing or body 20 defined by a cap 14 and a base 16. Cap 14 and base 16, as known in the art, may be configured for capturing therebetween a septum 18. As shown in FIG. 1A, cap 14 and base 16 may matingly engage one another along a mating line 15. Cap 14 and base 16 may be secured or affixed to one another via mechanical fasteners such as screws or other fastening devices, may be adhesively affixed to one another, or may be affixed to one another as known in the art. Further, cap 14, base 16, and septum 18 may collectively define a cavity 36 in fluid communication with a lumen 29 of outlet stem 31.

The body 20 may be implanted in a patient 7, as shown in FIG. 1B, to dispose the cavity 36 subcutaneously within the patient 7. Also, suture apertures 66 (FIG. 1A) may be used to affix the access port 10 within the patient 7, if desired. After the body 20 is implanted in a patient 7, the upper surface of the septum 18 may be substantially flush with the surface of the skin 6 of the patient 7 and may be repeatedly punctured for creating a percutaneous passageway from the exterior of the skin of the patient into the cavity 36. The outlet stem 31 may create a fluid-communicative passageway from the cavity 36 through the outlet stem 31 and into the interior of the patient 7. A catheter may be coupled to the outlet stem 31 for fluid communication with the cavity 36 and for transferring fluid from the cavity 36 to a desired remote location from the cavity 36 and within a patient 7.

Body 20 of access port 10 may comprise a bio-compatible material such as polysulfone, titanium, or any other suitably bio-compatible material as known in the art. Accordingly, the body 20 may be formed from a bio-compatible plastic material. If desired, the body 20 may comprise a penetrable material for penetration by sutures or needles. In another embodiment, and as discussed further hereinbelow, body 20 may comprise an impenetrable material such as, for instance, a metal if desired. Body 20 may include a concave bottom or, in another embodiment, may include a flat bottom, without limitation.

According to the instant disclosure, access port 10 may comprise a body 20 exhibiting at least one identifiable feature. More particularly, as shown in FIG. 1A, body 20 may exhibit a partial generally pyramidal shape (i.e., a polygonal base having surfaces for each side of the polygon extending toward a common vertex otherwise known as a frustum). Generally, a body 20 of an access port 10 may exhibit a partial pyramidal shape extending between a generally quadrilateral shaped base positioned at reference plane 11 and a generally quadrilateral shaped upper base positioned at reference plane 9. Reference planes 9 and 11 will not be shown in FIGS. 2-21, for clarity; however, reference to planes 9 or 11 with respect to FIGS. 2-21, as used herein, will refer to corresponding reference planes analogous to reference planes 9 and 11 as shown in FIGS. 1A and 1B.

As shown in FIG. 1A, the exterior of access port 10 is substantially defined by four substantially planar side surfaces 50 connected to one another by radiuses 32. In addition, the upper topography 61 of access port 10 is defined by upper surface 60 in combination with chamfers 46A and 46B and may be further defined by the upper surface of septum 18. Explaining further, the outer periphery of upper topography 61 may be described as a generally quadrilateral exterior formed by side regions 54 and having rounded corner regions 30 adjacent side regions 54. Such a configuration may provide an access port having at least one feature that may be perceived by palpation.

It may be appreciated that there are many variations to the geometry of access port 10 as shown in FIG. 1A. For instance, while the body 20 of access port 10 may be described as a partially pyramidal shape or frustum, the instant disclosure is not so limited. Rather, one or more of side surfaces 50 may be oriented at as may be desired, without reference to any other side surfaces 50. Accordingly, for example, one of surfaces 50 may be substantially vertical while the remaining surfaces 50 may be oriented at respective, selected angles. Furthermore, it should be understood that FIG. 1A is merely exemplary and that the dimensions and shape as shown in FIG. 1A may vary substantially while still being encompassed by the instant disclosure.

FIG. 2 shows a perspective view of another embodiment of access port 10 according to the instant disclosure. As shown in FIG. 2, the exterior of access port 10 is substantially defined by a generally parallelogram-shaped base (positioned at reference plane 11 as shown in FIGS. 1A and 1B) extending generally pyramidally to a generally parallelogram-shaped upper surface (positioned at reference plane 9 as shown in FIGS. 1A and 1B). As shown in FIG. 2, radiuses 42 may be larger than radiuses 32 as shown in FIG. 1A. Furthermore, the upper topography 61 of access port 10 as shown in FIG. 2 may include rounded corner regions 40 which are larger than rounded corner regions 30 as shown in FIG. 1A. Thus, FIG. 2 shows an exemplary embodiment of an access port 10 that may be perceivably distinguishable from access port 10 as shown in FIGS. 1A and 1B. For example, a difference between one exterior of an access port contemplated by the instant disclosure and another exterior of a different access port contemplated by the instant disclosure may be determined by way of palpation.

In another embodiment, in another aspect contemplated by the instant disclosure, a template may be employed for perceiving at least one feature of an access port. For instance, a complementarily-shaped template may be positioned over and abutted against an access port contemplated by the instant disclosure so as to determine if the access port matches or substantially corresponds to the shape of the template. Such a process may reliably indicate or perceive at least one feature of an access port contemplated by the instant disclosure. Of course, a plurality of templates corresponding to different models of access ports may be serially engaged with an unknown access port so as to perceive at least one feature thereof. Such a process may allow for identification (e.g., of a model or manufacturer) of an access port contemplated by the instant disclosure.

In another aspect contemplated by the instant disclosure, an upper topography of an access port may include at least one feature for identifying the access port. For example, as shown in FIG. 3, upper surface 60 of access port 10 may be nonplanar. More specifically, upper surface 60 may be tapered or may arcuately extend downwardly (i.e., toward reference plane 11 as shown in FIGS. 1A and 1B) as it extends radially inwardly toward septum 18. Otherwise, access port 10, as shown in FIG. 3, may be configured substantially as described hereinabove with reference to FIGS. 1A and 1B. Thus, upper surface 60 is one exemplary example of at least one perceivable feature for identification of an access port contemplated by the instant disclosure.

In yet a further embodiment of an access port contemplated by the instant disclosure, side regions 54 extending between rounded corner regions 30 may exhibit at least one perceivable feature. For example, as shown in FIG. 4, access port 10 may include one or more side regions 54 that extend arcuately between adjacent rounded corner regions 30. Otherwise, access port 10, as shown in FIG. 4, may be configured substantially as described hereinabove with reference to FIGS. 1A and 1B. Side regions 54 may be congruent or symmetric with respect to one another or, in another embodiment, may be configured differently with respect to one another, without limitation.

FIG. 5 shows a further exemplary embodiment of an access port contemplated by the instant disclosure. More specifically, access port 10, as shown in FIG. 5, includes side regions 54 that form recessed regions 72 between adjacent rounded corner regions 30. Put another way, the upper topography 61 may include alternating recessed regions 72 and protruding regions 70 positioned generally about a periphery of septum 18. Otherwise, access port 10, as shown in FIG. 5, may be configured substantially as described hereinabove with reference to FIGS. 1A and 1B. Such a configuration may provide an access port having at least one identifiable feature.

In a further embodiment of an access port contemplated by the instant disclosure, FIGS. 6A and 6B show a perspective view and a side view, respectively, of an access port 10 generally configured as is described with reference to FIG. 5 but having an elongated body 20E. More specifically, elongated body 20E of access port 10, as shown in FIGS. 6A and 6B, includes a side surface 50E that extends generally from upper topography 61 downwardly (i.e., toward reference plane 11 as shown in FIGS. 1A and 1B) and having a slope (e.g., an angle with respect to a vertical axis normal to an upper surface of septum 18) which is different from the other side surfaces 50. Otherwise, access port 10, as shown in FIG. 6, may be configured substantially as described hereinabove with reference to FIGS. 1A and 1B. Such a configuration may provide an elongated body 20E of an access port 10 having an elongated side portion.

Of course, one or more side surfaces of an access port according to the instant disclosure may be configured for forming a body exhibiting a selected shape as may be desired. An elongated body portion of an access port contemplated by the instant disclosure may form, in combination with other features as described hereinabove or, in another embodiment, taken alone, at least one perceivable feature for identification of an access port according to the instant disclosure.

FIG. 7 shows a further embodiment of an access port encompassed by the instant disclosure. Particularly, as shown in FIG. 7, access port 10 may include an upper body portion 20a and a lower body portion 20b. Furthermore, each of upper body portion 20a and lower body portion 20b may exhibit a partial pyramidal shape (i.e., a frustum), wherein the body portions 20a and 20b are stacked vertically with respect to one another. Accordingly, upper body portion 20a may form an overhanging rim feature 76 extending along a periphery of access port 10. Explaining further, lower body portion 20b may have an exterior substantially defined by side surfaces 50b and rounded corner regions 30b, while upper body portion 20a may have an exterior substantially defined by side surfaces 50a, rounded corner regions 30a, and upper topography 61. It may be appreciated that overhanging rim feature 76 may be sized and configured for perception via palpation. Such a configuration may provide a suitable access port for delivery of a beneficial or medicinal substance, the access port being identifiable (e.g., by model number, manufacturer, etc.) after implantation.

It should be understood that the instant disclosure contemplates access ports having an exterior geometry that is not quadrilateral in nature. Rather, the instant disclosure contemplates that an access port may have an exterior which is generally cylindrical, generally conical, generally elliptical, generally oval, or an exterior that is otherwise arcuate in nature. Specifically, the instant disclosure contemplates that an access port having a substantially rounded or arcuate exterior may include at least one feature configured for identification of the access port after implantation. For example, as shown in FIG. 8, shows a cap 14 that exhibits an exterior surface 78 that is substantially conical. Cap 14 may be assembled to a suitable base (not shown) for capturing a septum (not shown) as described hereinabove to form an access port 10 as generally described with reference to FIGS. 1-7.

The instant disclosure further contemplates that at least one protrusion, protruding region, recess, recessed region, undulation, or adjacent features of different elevation may comprise a feature for identifying an access port contemplated by the instant disclosure. More specifically, upper topography 61C, as shown in FIG. 8, may include a plurality of protrusions 80. Protrusions 80 may exhibit partially spherical upper surfaces that transition into a lower portion of cap 14. In further detail, protrusions 80 may be circumferentially spaced about the periphery of septum (not shown) as may be desired. In one embodiment, a plurality of protrusions 80 may be symmetrically circumferentially spaced about the periphery of septum (not shown). More generally, at least one protrusion 80 may be sized, configured, and positioned for forming at least one identifiable feature of an access port. Of course, at least one protrusion 80 may be structured for facilitating comfort of a patient within which the access port is implanted. As may be appreciated, at least one protrusion 80 or more than one protrusion 80 may be included in an upper topography 61C of an access port (not shown) contemplated by the instant disclosure.

FIG. 9 shows another embodiment of a cap 14 including at least one protrusion 80E for forming and identifying an access port contemplated by the instant disclosure after implantation thereof within a patient. Protrusions 80E may extend circumferentially about a center of revolution. Thus, protrusions 80E may exhibit a body 87 portion circumferentially extending between rounded ends 83. Further, cap 14 may have an exterior surface 78 that is substantially symmetric about an axis of revolution. More generally, body 20 may extend from a generally circular, generally elliptical, or generally oval base positioned at a lower extent 71 of the cap 14 to an upper generally circular, generally elliptical, or generally oval cross section that is smaller than a cross section of the base and is positioned at an upper extent 73 (without considering protrusions 80E) of the cap 14. In addition, side surface 51, as shown in FIG. 9, extends arcuately between the base and the upper topography 61 of cap 14. Side surface 51 may extend in a generally tapered or conical fashion, may exhibit a radius or other arcuate shape, or may otherwise transition between a cross section of the base of the access port to a cross section proximate the upper topography 61C thereof.

Further, FIG. 10 shows an embodiment of a cap 14 for forming an access port contemplated by the instant disclosure having an upper topography 61C thereof comprising alternating circumferentially extending protrusions 80E and circumferentially extending recesses 82, wherein the circumferentially extending protrusions 80E are circumferentially larger than the circumferentially extending recesses 80E. In another embodiment of an access port contemplated by the instant disclosure, FIG. 11 shows a perspective view of a cap 14 having an upper topography 61C thereof comprising alternating circumferentially extending protrusions 80E and circumferentially extending recesses 82, wherein the circumferentially extending protrusions 80E and the circumferentially extending recesses 82 are substantially equal in (circumferential) sized or extension. In yet a further embodiment of a cap 14 for forming an access port contemplated by the instant disclosure, FIG. 12 shows a perspective view of a cap 14 having an upper topography 61C thereof comprising three circumferentially extending protrusions 80E and three circumferentially extending recesses 82, arranged so as to alternate circumferentially, wherein the circumferentially extending protrusions 80E and the circumferentially extending recesses 82 are substantially equal in (circumferential) size.

FIG. 13 shows a perspective view of an additional embodiment of an cap 14 for forming an access port contemplated by the instant disclosure including an upper topography 61C including circumferentially extending protrusions 80T and circumferentially extending recesses 82T, wherein transition regions 81 are provided between circumferentially extending protrusions 80T and circumferentially extending recesses 82T. Such transition regions 81, as shown in FIG. 13, may taper or generally smoothly transition between a circumferentially extending protrusion 80T and a circumferentially extending recess 82T. Also, FIG. 14 shows a perspective view of an additional embodiment of a cap 14 for forming an access port contemplated by the instant disclosure including an upper topography 61C including protrusion regions 96 and recessed regions 98 that transition between one another and alternate circumferentially so as to form an undulating topography comprising upper topography 61C. Such an undulating topography, as shown in FIG. 14, generally smoothly transitions between circumferentially adjacent protrusion regions 96 and recessed regions 98.

In a further embodiment of an access port contemplated by the instant disclosure, FIGS. 15A and 15B show a perspective view and a top elevation view, respectively, of an access port 10 generally configured as is described with reference to FIG. 5 but may include at least one nonplanar side surface. In another embodiment, access port 10 as shown in FIG. 15 may be configured as shown in FIGS. 1-4 or FIGS. 6-7, or any embodiments described hereinbelow, without limitation. More specifically, elongated body 20 of access port 10, as shown in FIGS. 15A and 15B, includes three side surfaces 50R that extend arcuately (as shown in FIG. 15B). Such a configuration may provide an access port 10 that is identifiable subsequent to implantation. In yet another embodiment of an access port contemplated by the instant disclosure, FIG. 16 shows a perspective view of an access port 10 including a side wall 100 that truncates a portion of a radius 32 formed between side surfaces 50 of access port 10. It may also be noted that such an access port 10 may include three suture apertures 66, which may, taken alone or in combination with at least one other feature, comprise at least one identifiable feature of an access port contemplated by the instant disclosure. In addition, as shown in FIG. 16, outlet stem 31 may extend from side wall 100.

In a further embodiment of an access port contemplated by the instant disclosure, FIG. 17 shows a perspective view of an access port 10 wherein cap 14 and base 16, when assembled to one another along mating line 15, form a flange feature or lip feature 102 that extends about at least a portion of the periphery of the access port 10. As shown in FIG. 17, lip feature 102 extends substantially about the periphery of the access port 10, proximate to the mating line 15 between cap 14 and base 16. Such a feature may comprise at least one identifiable feature of an access port contemplated by the instant disclosure. Thus, it may be appreciated that a peripheral discontinuity between the cap 14 and base 16 may be formed generally along the mating line 15 therebetween. In the embodiment of an access port as shown in FIG. 7, an overhanging rim feature 76 may comprise a peripheral discontinuity or, in the embodiment of an access port as shown in FIG. 17, a lip feature 102 may comprise a peripheral discontinuity.

In a further embodiment of an access port contemplated by the instant disclosure, FIG. 18 shows a perspective view of an access port 10 wherein at least a portion of at least one side surface 50 is concave. As shown in FIG. 18, concave region 106 of side surface 50 is concave. Concavity (i.e., a concave region 106) may be exhibited over at least a portion of a side surface of an access port of any of the embodiments as shown herein, without limitation. Thus, at least one side surface 50 of an access port contemplated by the instant disclosure having at least at least a portion thereof that is concave is one exemplary example of at least one perceivable feature for identification of an access port contemplated by the instant disclosure.

In a further embodiment of an access port contemplated by the instant disclosure, FIG. 18 shows a perspective view of an access port 10 wherein at least a portion of at least one side surface 50 is concave. As shown in FIG. 18, region 106 of side surface 50 is concave. Concavity may be exhibited over at least a portion of a side surface of an access port of any of the embodiments as shown herein, without limitation. Thus, at least one side surface 50 of an access port contemplated by the instant disclosure having at least at least a portion thereof that is concave is one exemplary example of at least one perceivable feature for identification of an access port contemplated by the instant disclosure.

In a further embodiment of an access port contemplated by the instant disclosure, FIG. 19 shows a perspective view of an access port 10 generally configured as is described with reference to FIGS. 6A and 6B. More specifically, elongated body 20ER, as shown in FIG. 19 includes a side surface 50ER that extends arcuately from upper topography 61 of access port 10 downwardly (i.e., toward reference plane 11 as shown in FIGS. 1A and 1B). Such a configuration may provide an elongated body 20E of an access port 10 having an elongated side portion.

It should be understood from the above-described various embodiments of an access port contemplated by the instant disclosure that many variations, additions, or different features may be encompassed by the instant disclosure. Thus, the instant disclosure is not limited to the several above-described exemplary embodiments.

For example, as shown in FIG. 20, which shows a top elevation view of an access port 10 contemplated by the instant disclosure, an access port 10 may include a side wall 100 that at least partially truncates a radius 32 between side surfaces 50, outlet stem 31 extending from side wall 100, and at least one of a concave region 106 and an arcuate surface 50R. Further, as shown in FIG. 20, suture apertures 66 may be positioned so as to identify the access port 10 after subcutaneous implantation.

Additionally, the instant disclosure contemplates access ports having an exterior geometry that is polygonal in nature. Specifically, the instant disclosure contemplates that an access port contemplated by the instant disclosure may exhibit a generally triangular exterior. Thus, as shown in FIG. 21, body 20 may exhibit a generally pyramidal or tapered shape (i.e., a polygonal base having surfaces for each side of the polygon extending toward a common vertex). Generally, a body 20T of an access port 10 may extend between a generally triangularly-shaped base and a relatively smaller, generally triangularly-shaped upper base. Accordingly, the exterior of access port 10 may be substantially defined by three side surfaces (e.g., 50, 50R, 102, 50E) having radiuses 32 extending therebetween. In addition, the upper topography 61 of access port 10 may be defined by upper surface 60 in combination with side regions 54 and rounded corner regions 30. Such a configuration may provide an access port having at least one feature that may be perceived by palpation.

FIGS. 22 and 23 show a perspective view and a top elevation view of another embodiment of an access port including a generally triangular exterior geometry. More particularly, as shown in FIGS. 22 and 23, a cap 14 and base 16 (collectively forming a housing) may capture a septum 118 to form an access port 10. Further, outlet stem 31 may include a stem base that may be positioned within and sealed to an outlet recess 93 formed within base 16. The outlet stem 31 may be in fluid communication with a cavity formed within the access port 10. Optionally, suture plugs 89 may be positioned within suture cavities 91 formed in base 16. Suture plugs 89 may comprise a pliant material (e.g., silicone, rubber, etc.) that may provide some resilience between sutures coupling the access port 10 (i.e., the base 16) to a patient. In further detail, a side periphery 95 (e.g., one or more side walls) of access port 10 may be generally triangular. Thus, cap 14 and base 16 may collectively form a generally triangular housing or body of access port 10. Also, the instant disclosure contemplates that side periphery 95 may increase or decrease in cross-sectional size (e.g., by tapering or arcuately transforming) between upper surface 161 of cap 14 and lower surface 151 of base 16. As shown in FIGS. 22 and 23, a transverse cross section (taken in a selected plane substantially parallel to lower surface 151 of base 16) of access port 10 may be larger proximate to lower surface 151 of base 16 and may be relatively smaller proximate upper surface 161 of cap 14.

Additionally, FIG. 24 shows a simplified representation of a transverse cross section of access port 10. As shown in FIG. 24, side periphery 95 of access port 10 may define three side regions 103 that extend between associated vertex regions 101. In addition, in one embodiment and as shown in FIG. 24, side periphery 95 may define a substantially equilateral generally triangular shape. As one of ordinary skill in the art will appreciate, side regions 103 may arcuately extend between associated vertex regions 101; thus, side regions 103 may form “sides” of a generally triangular shape. Further, although vertex regions 101 are rounded, it may be appreciated that such vertex regions 101 form an intersection between adjacent side regions 103. Accordingly, one of ordinary skill in the art will appreciate that the phrase “generally triangular,” as used herein, encompasses any generally three-sided geometry wherein adjacent sides intersect, without limitation. For example, the phrase “generally triangular” encompasses three sided polygons, circular triangles, equilateral triangles, etc., without limitation.

The instant disclosure also contemplates that at least one feature of an access port contemplated by the instant disclosure may not be observable visually or by palpation but, rather, may be otherwise observable. For example, the instant disclosure contemplates that at least one feature of an access port may be observable through interaction with an imaging technology such as x-ray or ultrasound. For example, in one embodiment, a metal feature (e.g., a plate or other metal geometry) may be included by an access port contemplated by the instant disclosure. As may be appreciated, such a metal feature may be represented on an x-ray generated by exposure of the access port to x-ray energy while simultaneously exposing x-ray sensitive film to x-ray energy passing through the access port. Further, the instant disclosure contemplates that a size, shape, or both size and shape of a metal feature of an access port may be configured for enhancing identification of an access port. For example, assuming that a metal feature comprises a metal plate, a size, shape, or both may be selectively tailored for identification of an access port. Similarly, a feature of an access port contemplated by the instant disclosure may be tailored for detection via ultrasound interaction. Such a feature may comprise an exterior topographical feature. In another embodiment, such a feature may comprise a composite structure including two or more materials that form an interface surface that may be identified by ultrasound imaging.

One example embodiment of a feature observable through interaction with imaging technology contemplated by the instant disclosure is shown in FIGS. 52, 53A, and 53B. FIG. 52 depicts a bottom perspective view of an access port 10. FIG. 53A shows a top view of the access port 10, while FIG. 53B shows a bottom view of the access port. The access port 10 of FIGS. 52, 53A, and 53B is similar in some respects to the access port 10 as seen in FIGS. 22 and 23, including a cap 14 and a base 16 that cooperate to define a body. In the present example embodiment, however, the lower surface 151 of the base 16 includes an identification feature 200, as seen in FIGS. 52 and 53B. It is contemplated that the identification feature 200 can be one or more alphanumeric characters, such as the “CT” depicted. Additionally, the instant disclosure contemplates the use of other markings, such as one or more symbols, patterns, characters, designs, a combination thereof, etc. The identification feature 200 can be of any size, shape, or both in order to tailor the identification feature for the specific identification of one or more of a variety of characteristics of the access port. Specifically, in one embodiment the identification feature 200 can convey information to a practitioner regarding the power-injectability of the implanted access port. Note that in the present embodiment, the identification feature 200 is defined as a recessed feature, whereas in other embodiments the identification feature may be defined in other ways, as discussed hereafter.

As mentioned above, FIG. 53A depicts a top view of the access port 10. Note that the identification feature 200 is not observable through the upper surface 161 of the cap 14 or through the septum 118 without the interaction of imaging technology. As seen in FIG. 53B, the alphanumeric characters of the identification feature 200, “CT,” are engraved mirror-reversed on the lower surface 151 of the base 16. The “CT” is engraved mirror-reversed so that when imaging technology, such as x-ray imaging, is used to identify a subcutaneously implanted access port, the “CT” will be visible in the proper orientation. By engraving a desired identification feature mirror-reversed on the bottom surface of an access port, a practitioner will be able to determine if there is a problem with the port after implantation, such as if the access port has flipped or otherwise become mis-oriented while in the body of the patient. Thus, if the identification feature is seen mirror-reversed or askew in an x-ray image, the practitioner can correct the problem before attempts are made to use the access port.

Although also useful in access ports where only a portion of a port includes a metallic material, e.g., a metal plate, the engraving technique is well-suited in one embodiment for access ports that are composed of solid metal, such as titanium, stainless steel, or other materials that are typically radiopaque, i.e., non-transmissive to x-rays in sufficient thickness. FIGS. 54A-54C are representative images of the access port 10 of FIG. 52, which includes titanium or other metallic material, as seen via x-ray imaging after implantation into the patient. The access port 10 includes the identification feature 200 as seen in FIGS. 52 and 53B. Due to the relative thickness of the access port 10, the material of the base 16 and cap 14 surrounding a cavity periphery 36A of the cavity 36, which is a fluid cavity, is substantially non-transmissive to x-rays and therefore appears relatively dark in the x-ray image of FIG. 54A. However, the material of the access port 10 within the cavity periphery 36A is relatively thinner through a cavity base 220 (as seen in FIG. 55) than through the material of the cap 14 and base 16. Thus, additional thinning of the material when creating the identification feature 200 enables the identification feature to appear relatively more radiographically transmissive than the surrounding material of the cavity base under x-ray imaging. Note that the identification feature 200 in FIG. 54A is visible in the proper orientation, indicating that the access port is not flipped.

FIGS. 54B and 54C are additional representative x-ray images of the identification feature 200 of the access port 10, wherein the access port is tilted at angles of approximately 20 and 50 degrees, respectively. Thus, the identification feature 200 is also useful for determining relative orientation of the access port 10 after implantation.

FIG. 55 shows a cross-sectional view taken at line 55-55 of the access port 10 in FIG. 52. In this example embodiment, the identification feature 200 is disposed beneath the septum 118 and the cavity 36. FIGS. 56A and 56B further depict enlarged cross-sectional views of potential cut profiles of the recessed identification feature 200. FIG. 56A shows a rounded engraving profile 201, engraved on the lower surface 151 of the base 16 and used for purposes of aesthetics and ease of manufacturing. For a relatively more defined contrast under imaging technology, however, a sharp-edged engraving profile 202 may be used, as seen in FIG. 56B. Note that a variety of cross-sectional recessed profiles may be employed. This disclosure further contemplates that although engraving is discussed here, other methods of marking the identification feature may be used, such as milling, machining, chemical or laser etching, molding, stamping, etc.

Regardless of the cut profile used, better contrast is achieved generally with greater engraving depth X. The optimal engraving depth X will depend, however, on the thickness of the overall cavity base 220, which is the portion of the base directly below the cavity 36, as shown in FIG. 55. For example, in an embodiment of an access port including titanium, if the overall thickness of the cavity base 220 is approximately 0.020″ then sufficient contrast for x-ray imaging purposes can be obtained in one embodiment by engraving the identification feature 200 to a depth X (FIGS. 56A, 56B) of between about 0.009″ and about 0.011″. In another example embodiment of an access port including titanium, where the overall thickness of the cavity base 220 is approximately 0.030″, sufficient contrast can be obtained by engraving the identification feature 200 to a depth X of between about 0.015″ and about 0.021″. One of ordinary skill in the art will appreciate that the depth of an engraved identification feature can be varied substantially in order to comply with a product's safety requirements and still remain within the scope contemplated by this disclosure. In addition, the depth X of the identification feature can vary according to the position of the feature on the access port, the thickness of material to be penetrated by the imaging technology, the type of material included in the access port, etc.

It is also contemplated by this disclosure that the use of an identification feature in a metallic or other radiopaque access port can be applied to access ports having a variety of possible configurations, such as is seen in FIGS. 57A-58C, for example. FIGS. 57A-57C depict one embodiment, wherein the access port 10 includes an identification feature 200 on a lower surface 251 of a base or body 116. The access port 10 in FIGS. 57A-57C includes a retaining ring 230, which seals the septum 118 to the base or body 116, over the cavity 36. In one embodiment, the retaining ring 230 is press fit into the base or body 116 to hold the septum 118 in place. FIGS. 58A-58C show yet another embodiment, wherein the access port 10 includes an identification feature 200 on the cavity base 220 and wherein the cavity base is mated to and flush with a lower surface 252 of a cap 114 to define a body. In a particular embodiment, the cavity base 220 is press fit into the cap 114, though other mating configurations can also be employed.

In another embodiment contemplated by the instant disclosure, FIGS. 59A and 59B show that the location of the identification feature 200 can vary as well. Rather than placing the identification feature 200 under the cavity 36, it is possible to place the identification feature under another portion of the access port 10, such as under the outlet stem 31 and between the septum plugs 89, i.e., proximate the outer periphery of the access port bottom surface. Though the overall thickness of the access port structure above the identification feature 200 is greater in this location than if engraved under the cavity 36, the change in location allows for a relatively deeper engraving, which will increase contrast without risk of excessive thinning of the cavity base 220. Additionally, in one embodiment, it is possible to define the identification feature compositely by engraving into both the bottom and top surfaces, such that the engravings are vertically aligned. This enables the remaining material thickness to be substantially reduced in order to provide relatively greater radiographic transmission through the identification feature.

Additionally, the instant disclosure contemplates access ports having any variety or combination of desired identification features for indicating power-injectability or other aspect or characteristic of an access port. Specifically, FIGS. 60A-61B depict different types of identification features 200, according to example embodiments. FIGS. 60A-60B depict a symbolic identification feature 200. FIGS. 61A-61B depict an exemplary embodiment of an access port 10 including a combination of identification features 200, namely an alphanumeric identification feature 200A and a patterned identification feature 200B. A patterned or symbolic identification feature can also be used to help indicate the orientation of the port or for any other desired reason. It is understood by the instant disclosure that other symbols, patterns, marks, and alphanumeric characters can be used both alone and in any combination with each other on a variety of access port configurations.

In additional embodiments, the identification feature can be defined on an inside bottom surface 36B of the cavity 36 of an access port 10, or in addition to the identification feature 200 provided on the bottom surface 251. In another embodiment, the material surrounding the defining edges of the desired radiopaque alphanumeric character, symbol, pattern, etc., can be removed instead of removing the desired feature shape itself so as to define a “positive” relief image of the identification feature. Such a positive relief identification feature can be defined on a lower surface of an access port body or on the inside bottom surface of the cavity, for example.

In addition to the various types of symbols, patterns, marks, and alphanumeric characters that are contemplated by the instant disclosure, FIGS. 62A-63C disclose additional example embodiments of identifying features on access ports that are observable via x-ray or other suitable imaging technology. Specifically, the instant disclosure contemplates the use of shelled-out cavities 204, wherein portions of the access port 10 are hollowed out. This results in shelled-out cavities 204 extending inward from the lower surface 251 of the base or body 116 or corresponding port lower surfaces of the other embodiments described herein, including the lower surface 151 of the base 16, as in FIG. 151, and the lower surface 252 of a cap 114, as in FIGS. 58A-58C. This is done by removing the material surrounding the cavity 36 without disrupting the cavity periphery 36A or the outer side surfaces 250 of the access port 10. As seen in FIG. 62B, ribs 240 may be left to support the remaining “shelled” frame of the access port 10. The definition of such cavities 204 provides a relative difference in radiopacity of the access port 10 that can be identified via x-ray imaging. As such, the cavities 204 can be arranged to define a pattern or to form an indicia for identification of an aspect or characteristic of the access port 10. Note that in other embodiments, the cavities can be defined so as to extend from other surfaces of the access port, including the top and sides thereof.

In a further aspect contemplated by the instant disclosure, it is contemplated that a communicative technology may be utilized wherein information is encompassed by an access port contemplated by the instant disclosure. Generally, a communication device (e.g., a radio beacon, a light-emitting element, an ultrasound emitting transducer, etc.), may be imbedded or otherwise affixed to an access port contemplated by the instant disclosure. Such a communication device may be configured for transmitting information in response to a given impetus. More specifically, the instant disclosure contemplates that an access port contemplated by the instant disclosure may be exposed to a request signal (e.g., a sound, an impact or an acceleration, light, radio waves, etc.). Such a request signal may cause the communication device to transmit information therefrom via sound, light, radio waves, or as otherwise known in the art. Such information may be employed for identifying an access port contemplated by the instant disclosure.

In one exemplary example, it is contemplated that radio frequency identification technology may be employed for identification of an access port contemplated by the instant disclosure. Particularly, so-called active RFID tags are powered by an internal battery and are typically read/write devices. Currently, a suitable cell coupled to suitable low power circuitry can ensure functionality for as long as ten or more years, depending upon the operating temperatures and read/write cycles and usage. So-called passive RFID tags operate without a separate external power source and obtain operating power generated from the reader. Passive RFID tags are typically programmed with a unique set of data (usually 32 to 128 bits) that cannot be modified. Read-only tags may operate as an identifier comparable to linear barcodes which may contain selected product-specific information. Thus, passive RFID tags may be much lighter than active RFID tags, less expensive, and may offer a virtually unlimited operational lifetime. The tradeoff is that they have shorter read ranges than active tags and require a higher-powered reader.

One advantage of RFID approach is the noncontact, non-line-of-sight nature of the technology. Tags can be read through a variety of substances such as snow, fog, ice, paint, crusted grime, and other visually and environmentally challenging conditions, where other optically read technologies may be less effective. RFID tags can also be read in challenging circumstances at rapid speeds, in most cases responding in less than about 100 milliseconds.

Reference is now generally made to FIGS. 64-75C in describing additional embodiments wherein an access port includes at least one identification feature observable through interaction with an imaging technology, such as x-ray and fluoroscopy, for instance, in order to facilitate identification of at least one attribute, or characteristic, of an access port subsequent to implantation within the body of a patient. It is appreciated that the embodiments to be described can be included alone or together with other identification features described herein and may be employed with access ports having a variety of sizes, shapes, and other variations in configuration. As such, the embodiments described herein are merely examples of the principles of the present disclosure.

FIG. 64 shows an access port 310 including a base 316 and a septum 318 covering a reservoir defined by the base. The septum 318 includes a plurality of palpation bumps 320 for enabling external digital palpation and location of the septum by a clinician after the access port 310 has been subcutaneously implanted. The port 310 includes a retaining ring 330 for capturing and retaining the septum 318 in place atop the port reservoir. In the present embodiment, both the port base 316 and the retaining ring are metallic substance, including titanium for instance, though in other embodiments other suitable materials may be used.

In the present embodiment the retaining ring 330 includes an identification feature 200 for identifying a predetermined attribute or characteristic of the port 310 after implantation thereof. Specifically, the retaining ring 330 includes alphanumeric character identification features 200A spelling “POWER INJECTABLE,” which indicates that the port 310 is capable of power injection. The alphanumeric characters in one embodiment are inset via etching or otherwise suitably defined in the retaining ring 330 so as to provide a relative thickness difference between the characters and surrounding metallic retaining ring material, thus providing a corresponding radiographic contrast when the port 310 is imaged with x-ray imaging technology. This contrast enables the alphanumeric characters to become visible in an x-ray and therefore discernible by a clinician viewing the x-ray, thus enabling the port attribute or characteristic relating to the identification feature 200 to be ascertained.

Note that the alphanumeric identification features 200A can be defined on the retaining ring 330 in any number of suitable ways, including etching, engraving, etc., and the characters can be defined partially or completely through the retaining ring. Also, the particular characters or words used can vary from what is described here. Indeed, other characters, patterns, symbols, etc. can be employed in the identification feature 200. Optionally, the identification features can be defined in negative relief, as shown in FIG. 64, or in positive relief, if desired.

Additionally, in other embodiments the identification feature of the retaining ring can be configured in other ways according to the configuration of the port. For instance, in embodiments where the port body includes a non-metallic material, the identification feature can include radiopaque ink that is applied to a surface of the retaining ring so as to form the alphanumeric or other characters or features. In yet other embodiments, the identification feature can be included on portions or surfaces of the port in addition to the retaining ring. These and other modifications are therefore contemplated.

FIG. 65 includes the metallic retaining ring 330 of the metallic port 310 configured in accordance with another embodiment, wherein the retaining ring defines the identification feature 200, including a plurality of overlapping portions 330A that each overlap a portion of the septum 318 retained by the retaining ring. In FIG. 65, the overlapping portions 330A of the retaining ring 330 cooperate to generally define a triangular shape, which provides a radiographic contrast relative to portions of the metallic port 310 below the retaining ring. As before, this provides a corresponding radiographic contrast when the port 310 is imaged with x-ray imaging technology, enabling the triangular shape to be discernible as a radiopaque outline by a clinician viewing the x-ray in order to ascertain the predetermined port attribute or characteristic relating to the identification feature 200 to be ascertained. In other embodiments, the retaining ring can define other shapes in addition to the triangular shape shown here. Additionally, characters, symbols, or other patterns can be defined in or included on the overlapping portions of the retaining ring if desired.

FIGS. 66A-66D depict various details regarding the inclusion of an identification feature for identifying a predetermined attribute or characteristic of an access port after implantation into a patient. Specifically, these figures depict a dual reservoir access port 410, including a cap 414 matable to a base 416 and two septa 418 interposed between the cap and base. Suture plugs 422 are included with the port 410. In accordance with the present embodiment, a bottom surface 416A of the port base 416 includes the identification feature 200 for identification of the subcutaneously implanted port. As best seen in FIG. 66B, the identification feature 200 in the present embodiment includes a radiopaque marking including the letters “C” and “T” outlined by a double-triangle border, though many different character, pattern, and/or combination configurations are possible. For instance, in addition to identifying the access port as power injectable, this and other identification features described herein can be used to designate lot numbers, hospital identification, port brand, etc.

The radiopaque marking of the identification feature 200 can include a metallic powder intermixed with an ink-based marking. Specifically, in one embodiment, the radiopaque marking includes tungsten powder intermixed with 1020 black wire marking ink manufactured by Gem Gravure, Inc. of West Hanover, Mass., in a ratio of three parts tungsten powder to one part ink. Mixing of the two components can include ball mixing to ensure good component integration in one embodiment. Also, additives can be added to the mixture to attain a proper mixture viscosity.

In other embodiments, the powder-to-ink ratio can be modified from that described above, including 2:1, 4:1, and 5:1 ratios, for instance. The ideal ratio will vary according to the type of materials employed in the mixture, the density of the desired image, powder particle size, amount of mixture applied to the port, etc. In yet other embodiments, other medical grade inks or suitable liquids, as well as other biocompatible metallic powders or suitable radiopaque materials, could be used. In one embodiment, a ceramic, such as zirconium oxide powder, can be intermixed with a marking ink to provide the radiopaque marking. Ink thinners can also be added to the mixture, along with other suitable substances as appreciated by those skilled in the art.

As shown in FIG. 66B, the ink-based radiopaque marking that forms the identification feature 200 in the present embodiment is included on a substrate 440. In one embodiment, the substrate 440 includes a material substantially identical to the material included in the port 410. Specifically, in one embodiment, both the port 410 and the substrate 440 include an acetyl resin sold under the brand DELRIN®, though it is appreciated that other suitable materials could be used for the substrate and port.

The substrate 440 is employed as a base on which the radiopaque marking can be deposited in preparation for integration of the substrate and marking into the port 410 during an injection molding process so as to encapsulate the radiopaque marking within the molded port. In detail, in one embodiment, the radiopaque marking, including the above-described ink/powder mixture or other suitable substance, is first deposited on a surface of the substrate 440 via any acceptable process, including pad printing, manual or automatic painting, silk screening, use of a template, etc. To improve adhesion of the ink/powder mixture, the substrate can be plasma treated or corona treated in one embodiment.

Once the radiopaque marking has been applied to the substrate 440, the substrate is loaded into a mold, such as that shown in FIG. 66C, which depicts the substrate positioned within a cavity 444 of a portion of a mold 442. The substrate 440 is positioned within the mold cavity 446 such that the radiopaque marking is facing in toward what will become the center of the port 410. In one embodiment, the substrate 440 is held in place within the mold cavity 444 via a vacuum assist system; in other embodiments, temporary mechanical fixation can be employed, if necessary. A template including a hole sized to enable the substrate to pass therethrough can be used in one embodiment to assist the technician in placing the substrate 440 with the proper orientation within the mold cavity 444.

The port 410 is then fabricated by an injection molding process. The substrate 440 is thus insert-molded into the port 410 via the injection molding process, which bonds the substrate 440 to the molded body of the port 410, thus encapsulating the radiopaque marking of the identification feature 200 within the port and preventing its inadvertent removal. Additionally, due to the relative thinness of the substrate 440, the identification feature remains visible through the substrate from outside of the port 410, as seen in FIG. 66D, before implantation. In one embodiment, the thickness of the substrate 440 ranges from about 0.002 inch to about 0.015 inch, though other thicknesses can be acceptably used. Later, when the port 410 is implanted and imaged under x-ray, the identification feature 200 will be visible in the x-ray image and useful to identify an attribute or characteristic of the implanted port.

It is appreciated that in other embodiments, the substrate can be configured to be positioned in other regions of the port. In yet other embodiments, other substrate materials can be used. For instance, in one embodiment the substrate can include woven high-density polyethylene sold under the brand TYVEK®. In this case, the substrate 440 does not permanently adhere to the port 410 as a result of the insert molding process, but is removed after molding process is complete. The radiopaque marking ink/powder mixture initially included on the woven substrate 440, however, is integrated into the port body and remains with the port 410 after molding and substrate removal to serve as the identification feature 200. Flaps or flanges can be included on the substrate to facilitate its separation from the substrate from the port after molding, in one embodiment. In another embodiment, the ink/powder radiopaque marker mixture is allowed to dry on the substrate 440 after application thereon to improve adhesion to the port 410 during the insert molding process. In addition to those explicitly described here, other suitable materials can be used as the substrate. In yet another embodiment, no substrate is used and the ink/powder radiopaque marker mixture is applied directly to the mold surface before the port 410 is molded therein.

FIGS. 74A and 74B depict details of the substrate 440 and identification feature 200 configured in accordance with another embodiment, wherein the substrate forms a portion of the port base. A raised surface 440A is included on the substrate, and a radiopaque marking, such as the intermixed marking ink and radiopaque powder, is included on the raised surface to define the identification feature 200. Application of the radiopaque marking can occur in any one of a number of suitable ways, including contact application by a stamp or tamp pad, ink jet printing, physical or chemical deposition, etc.

The substrate 440 with the included identification feature 200 can then be inserted into a mold and insert-molded to form part of a base 616 of an access port. The radiopaque identification feature 200, now encapsulated within the base, provides the desired identification of a predetermined attribute or characteristic of the port once manufacture of the port is complete.

Reference is now made to FIG. 67, which depicts another identification feature for an access port, such as a plastic port for instance, according to one embodiment. In particular, the port 410 of FIG. 67 includes a cavity 446 defined on a bottom surface 416A of the port base 416. In one embodiment, the cavity 446 is defined to a depth of about 0.010 inch, though other depths can also be used according to desire and port configuration. The cavity 446 is filled with a radiopaque fill material 448. The cavity 446 is shaped with a predetermined design or configuration so as to form the identification feature 200 when filled with the radiopaque fill material 448, thus enabling a predetermined attribute or characteristic of the port 410 to be identified via x-ray imaging subsequent to implantation. In the present embodiment, the fill material 448 includes tungsten powder intermixed with a two-part silicone sold under the brand SILASTIC® Q7-4840, available from Dow Corning Corporation, Midland, Mich. in equal quantities, i.e., equal parts of part A silicone, part B silicone, and tungsten powder. Of course, other suitable materials could also be employed. For instance, titanium can be used in place of tungsten, and biocompatible urethane adhesives can be used in place of silicone.

In one embodiment, the fill material 448 is injected into the cavity 446 by a pressurized syringe, such as an electronic fluid dispenser, though other suitable techniques can also be employed, including manual filling by syringe. Any excess fill material 448 can be removed from the port base bottom surface 416A after filling, and the fill material can be allowed to cure. Note that in other embodiments the bottom surface of the port can include other portions of the port in addition or instead of the base, as shown in FIG. 67.

FIGS. 68A-68C show details of one embodiment for providing the identification feature 200 on a resilient septum 468 of an implantable access port, such as a plastic port for instance, wherein the septum includes a radiopaque portion visible under x-ray imaging to provide information relating to an attribute or characteristic of the septum itself and/or the access port in which the septum is disposed. In the illustrated embodiment, the radiopaque portion is defined as an annular portion 470 disposed about the upper outer periphery of the septum 468 so as not to interfere with puncturing of the septum by needles during port use. As best seen in FIG. 68C, the annular portion does not extend in depth through the thickness of the septum outer portion, but in other embodiments the thickness, size, and position of the radiopaque portion can vary on the septum.

In the present embodiment, the radiopaque annular portion 470 includes barium sulfate-loaded silicone, while the remainder of the septum 468 is unloaded silicone. In other embodiments, other suitable radiopaque materials can be employed with silicone or other septum materials. In one embodiment, the septum 468 of FIGS. 68A-68C can be formed by a two-part molding process, wherein the annular portion 470 is manufactured separately from the rest of the septum 468, then the two parts are adhered together by a suitable adhesive, mechanical fixation, etc., to form the structure shown in FIGS. 68A-68C.

In another embodiment, the present septum 468 is manufactured integrally via a co-molding process, wherein separate injection heads are employed in a mold cavity in order to injection mold the annular portion 470 with one or more heads and the rest of the septum 468 with separate heads. These and other manufacturing methods are therefore considered within the spirit of the present disclosure.

The principles discussed in connection with FIGS. 68A-68C can be expanded in one embodiment shown in FIG. 69, wherein a port 510 including resilient suture plugs 522 disposed in corresponding suture plug holes 524 is configured such that the suture plugs include a radiopaque material, such as the barium sulfate-loaded silicone employed in the septum 468 of FIGS. 68A-68C or other suitable radiopaque material. So configured, the suture plugs provide the identification feature 200 that is visible under x-ray imaging to provide information relating to an attribute or characteristic of the port 510. In one embodiment, the port 510 can include both the radiopaque suture plugs 522 and the septum 468 including the radiopaque portion 470 in order to provide additional identification ability and/or to provide information relating to the orientation of the port within the body of the patient. In addition to barium sulfate, the suture plugs can include tungsten, tantalum, or other suitable radiopaque materials. In yet another embodiment, one or more radiopaque beads can be disposed in the port body to provide similar port visibility under x-ray.

In one embodiment, the septum, suture plugs, or other portion of the port can include an ultraviolet light-sensitive material. The ultraviolet light-sensitive material can be applied to the surface of the port component or can impregnated into the component. After implantation of the port, ultraviolet light is directed through the skin of the patient to be incident on the ultraviolet light-sensitive material of the port, which causes the material to fluoresce with visible light that is observable through the skin of the patient, thus identifying the port and/or its predetermined attribute or characteristic.

It is appreciated that a radiopaque identification feature can be included or associated with a port in other ways in addition to those embodiments already described. Examples of this can be found in the embodiments depicted in FIGS. 70-72. In FIG. 70, for example, an identifier tag 550 is shown, including a ring portion 552 with a slit 554 for enabling the identifier ring to be attached to a catheter that is operably attached to the stem of a port. The identifier tag 550 further includes a face portion 556 on which a radiopaque identification feature 200 can be placed for visibility via x-ray imaging to identify a predetermined attribute or characteristic of the port. The tag can be designed in various different shapes and configurations. For instance, the tag can be included as part of a catheter securement device for locking an end of a catheter to the stem of the port.

In FIG. 71, the port 510 is shown with a catheter securement device 540 that is used to secure the connection between an end of a catheter 512 and a stem 530 of the port. A body 542 of the catheter securement device 540 is configured to include the identification feature 200 for visibility via x-ray imaging to identify a predetermined attribute or characteristic of the port to which the device is attached. Again, the shape, size, and particular configuration of the catheter securement device and identification feature can vary from what is shown and described herein.

In FIG. 72, the port 510 is shown with the catheter 512 operably attached thereto. The catheter 512 includes two flaps 550 that extend from the body thereof, on which the identification feature 200 is included in order to provide a visible identification of a predetermined attribute or characteristic of the catheter and/or port when imaged under x-ray. Of course, the particular identification feature, as well as the number and size/configuration of the catheter flaps can vary from what is described herein.

FIGS. 73A and 73B depict yet another example of a radiopaque identification feature wherein the identification feature 200 is included in an insert 570 formed from a radiopaque material, such as tungsten or other suitable material. The insert 570 is suitable for placement in a plastic or other radiotranslucent port such that the insert is visible under x-ray imaging to identify an attribute or characteristic of the port. Orientation arrows 572 provide useful indicia of the orientation of the port. By examining the direction of the arrows 572, a clinician observing an x-ray image of the port insert 570 can determine whether the port is flipped in the body of the patient. In addition to these, other indicia indicating port orientation can be included on the insert in other embodiments.

FIGS. 75A-75C show implementation of another example of a radiopaque insert, in addition to that shown in FIGS. 73A and 73B, which is included to serve as the identification feature 200 for identifying a predetermined attribute or characteristic of a port, including a plastic port, as in the present embodiment. In particular, a radiopaque insert 670 is shown, configured to be interposed between a cap 714 and a base 716 of a port 710. Note that, though the insert 670 shown here is configured to fit over a dual fluid cavity 712 of the port 710, other inserts including a variety of radiopaque compositions can be configured to be included in other ways with a port. Additionally, the port can define one, two, or more fluid cavities covered by septa 718, without limitation.

As shown in FIG. 75B, the insert 670 fits over the fluid cavities 712 of the port 710 so as to rest on a portion of the port base 716. So positioned, the insert 670 is sandwiched and secured between the base 716 and the cap 714 when the base and cap are mated together to form the port 710. Such mating can be accomplished by ultrasonic welding, adhesives, etc. The resulting interposition of the insert 670 between the base 716 and cap 714 is shown in FIG. 75C. When the port 710 is later imaged via x-ray after patient implantation, the insert 670 is readily visible, thus enabling the predetermined attribute/characteristic(s) of the port to be identified.

While certain representative embodiments and details have been shown for purposes of illustrating aspects contemplated by the instant disclosure, it will be apparent to those skilled in the art that various changes in the methods and apparatus disclosed herein may be made without departing form the scope contemplated by the instant disclosure, which is defined in the appended claims. For example, other access port sizes and shapes may be employed; and various other embodiments and structures may be employed for forming at least one identifiable feature of an access port contemplated by the instant disclosure. In particular, FIGS. 25-51 illustrate a number of additional exemplary embodiments of access port 10. As is apparent from these figures, access port 10 may be formed in any number of shapes and sizes, such that any number of modifications and changes are possible to any of the embodiments described and illustrated herein without departing from the spirit and scope of the instant disclosure.

Claims

1. An access port for providing subcutaneous access to a patient, comprising: a port base defining a fluid cavity, the port base formed from a base material;a substrate separate from the port base formed from a substrate material, the substrate attached to the port base, the substrate including an inner surface facing toward the fluid cavity and an outer surface facing away from the fluid cavity; anda radiopaque material adhered to the substrate inner surface prior to attachment of the substrate to the port base, the radiopaque material including an identification feature.
2. The access port as defined in claim 1, wherein the substrate material includes an acetyl resin or a high-density polyethylene.
3. The access port as defined in claim 1, wherein the substrate material and the base material are substantially similar.
4. The access port as defined in claim 1, wherein the identification feature is visible through the substrate after attachment of the substrate to the port base.
5. The access port as defined in claim 1, wherein the substrate is insert molded with the port base, and wherein the radiopaque material includes a metallic powder intermixed with an ink.
6. The access port as defined in claim 5, wherein the metallic powder is tungsten powder and wherein the tungsten powder is intermixed with the ink at a ratio of three parts tungsten powder to one part ink.
7. The access port as defined in claim 1, wherein the identification feature includes the letters “C” and “T”.
8. The access port as defined in claim 7, wherein the letters are outlined by a double-triangle border.
9. The access port as defined in claim 1, wherein the identification feature identifies the access port as power injectable.
10. The access port as defined in claim 9, wherein the identification feature further identifies one or more of: the access port lot number, a hospital identification, and the access port brand.
11. The access port as defined in claim 1, wherein the substrate material comprises a woven material, and wherein the port base is insert molded over the substrate.
12. The access port as defined in claim 11, wherein the substrate is removed after the molding process is complete.
13. The access port as defined in claim 12, wherein the substrate includes flaps or flanges extending from the outer perimeter to facilitate separation of the substrate from the port.
14. A power injectable access port, comprising: a port base defining a fluid cavity, the port base formed from a base material;a substrate separate from the port base formed from a substrate material, the substrate material being the same as the base materiala radiopaque material deposited on a surface of the substrate, the radiopaque material including a feature identifying the access port as power injectable,wherein the substrate is coupled to the port base such that: the radiopaque material is encapsulated between the substrate material and the base material; andthe feature identifying the access port as power injectable is visible through the substrate prior to implantation.
15. The power injectable access port as defined in claim 14, further comprising a port cap positioned over the port base to capture a septum therebetween.
16. The power injectable access port as defined in claim 14, wherein the radiopaque material comprises a metallic powder intermixed with a marking ink.
17. The power injectable access port as defined in claim 14, wherein the radiopaque material is included on a raised surface of the substrate.
18. The power injectable access port as defined in claim 14, wherein the radiopaque material is deposited on the surface of the substrate via a process selected from the group consisting of pad printing, manual painting, automatic painting, and silk screening.
19. The power injectable access port as defined in claim 14, wherein the substrate has a thickness in the range from about 0.002 inch to about 01015 inch.

RELATED APPLICATIONS

This application is a division of U.S. patent application Ser. No. 12/610,084, filed Oct. 30, 2009, now U.S. Pat. No. 8,202,259, which claims the benefit of U.S. Patent Application No. 61/110,507, filed Oct. 31, 2008 and which is a continuation-in-part of U.S. patent application Ser. No. 12/420,028, filed Apr. 7, 2009, now U.S. Pat. No. 7,947,022, which is a continuation-in-part of U.S. patent application Ser. No. 11/368,954, filed Mar. 6, 2006, now U.S. Pat. No. 7,785,302, which claims the benefit of U.S. Patent Application No. 60/658,518, filed Mar. 4, 2005. Each of the afore-referenced applications is incorporated, in its entirety, by this reference.

US Referenced Citations (733)

Number	Name	Date	Kind
445896	Kinsman	Feb 1891	A
546440	Tufts	Sep 1895	A
574387	Buckler	Jan 1897	A
611357	Dembinski	Sep 1898	A
966696	Merrill	Aug 1910	A
1713267	Crowley	May 1929	A
2029553	Bartischi et al.	Feb 1936	A
2433480	Rendich	Dec 1947	A
2891689	Gould	Jun 1959	A
D198453	Weichselbaum	Jun 1964	S
3159175	Macmillan	Dec 1964	A
3293663	Cronin	Dec 1966	A
3341417	Sinaiko	Sep 1967	A
3477438	Allen et al.	Nov 1969	A
3518428	Ring	Jun 1970	A
3525357	Koreski	Aug 1970	A
3529633	Vailancourt	Sep 1970	A
3540670	Rissberger	Nov 1970	A
3541438	Nelsen et al.	Nov 1970	A
3643358	Morderosian	Feb 1972	A
3669323	Harker et al.	Jun 1972	A
3674183	Venable et al.	Jul 1972	A
3811466	Ohringer	May 1974	A
3829904	Ling et al.	Aug 1974	A
3831549	Parsons	Aug 1974	A
3831583	Edmunds, Jr. et al.	Aug 1974	A
3840009	Michaels et al.	Oct 1974	A
3853127	Spademan	Dec 1974	A
3891997	Herbert	Jul 1975	A
3915162	Miller	Oct 1975	A
3919724	Sanders et al.	Nov 1975	A
3922726	Trentani et al.	Dec 1975	A
3951147	Tucker et al.	Apr 1976	A
3955594	Snow	May 1976	A
3971376	Wichterle	Jul 1976	A
4027391	Samis	Jun 1977	A
4035653	Karasko	Jul 1977	A
4121108	Manor	Oct 1978	A
4123806	Amstutz et al.	Nov 1978	A
4143853	Abramson	Mar 1979	A
4168586	Samis	Sep 1979	A
4181132	Parks	Jan 1980	A
4190040	Schulte	Feb 1980	A
4190057	Hill et al.	Feb 1980	A
4194122	Mitchell et al.	Mar 1980	A
4196731	Laurin et al.	Apr 1980	A
4202349	Jones	May 1980	A
4222374	Sampson et al.	Sep 1980	A
4233964	Jefferts et al.	Nov 1980	A
4274006	Caine	Jun 1981	A
4349498	Ellis et al.	Sep 1982	A
4361153	Slocum et al.	Nov 1982	A
4405305	Stephen et al.	Sep 1983	A
4406567	Samis	Sep 1983	A
4425119	Berglund	Jan 1984	A
4445896	Gianturco	May 1984	A
4447237	Frisch et al.	May 1984	A
4450592	Niederer et al.	May 1984	A
4450985	Beard	May 1984	A
4456011	Warnecke	Jun 1984	A
4469483	Becker et al.	Sep 1984	A
4479798	Parks	Oct 1984	A
4494545	Slocum et al.	Jan 1985	A
4506676	Duska	Mar 1985	A
4529635	Sheldon	Jul 1985	A
4543088	Bootman et al.	Sep 1985	A
4549879	Groshong et al.	Oct 1985	A
4559046	Groshong et al.	Dec 1985	A
4560375	Schulte et al.	Dec 1985	A
4569675	Prosl et al.	Feb 1986	A
4571749	Fischell	Feb 1986	A
4576595	Aas et al.	Mar 1986	A
4610665	Matsumoto et al.	Sep 1986	A
4612877	Hayes et al.	Sep 1986	A
4626244	Reinicke	Dec 1986	A
4627844	Schmitt	Dec 1986	A
4634427	Hannula et al.	Jan 1987	A
4636194	Schulte et al.	Jan 1987	A
4636213	Pakiam	Jan 1987	A
4645495	Vaillancourt	Feb 1987	A
4653508	Cosman	Mar 1987	A
4655765	Swift	Apr 1987	A
4657024	Coneys	Apr 1987	A
4662652	Hargis	May 1987	A
4668221	Luther	May 1987	A
4671796	Groshong et al.	Jun 1987	A
4673394	Fenton, Jr. et al.	Jun 1987	A
4684365	Reinicke	Aug 1987	A
4685447	Iversen et al.	Aug 1987	A
4685905	Jeanneret nee Aab	Aug 1987	A
4692146	Hilger	Sep 1987	A
4695273	Brown	Sep 1987	A
4697595	Breyer et al.	Oct 1987	A
4701166	Groshong et al.	Oct 1987	A
4704103	Stober et al.	Nov 1987	A
4707389	Ward	Nov 1987	A
4710174	Moden et al.	Dec 1987	A
4718894	Lazorthes	Jan 1988	A
4723947	Konopka	Feb 1988	A
4728894	Yoda et al.	Mar 1988	A
4743231	Kay et al.	May 1988	A
4753640	Nichols et al.	Jun 1988	A
4755173	Konopka et al.	Jul 1988	A
4760837	Petit	Aug 1988	A
4762517	McIntyre et al.	Aug 1988	A
4767410	Moden et al.	Aug 1988	A
4772270	Wiita et al.	Sep 1988	A
4772276	Wiita et al.	Sep 1988	A
4773552	Boege et al.	Sep 1988	A
4778452	Moden et al.	Oct 1988	A
4781680	Redmond et al.	Nov 1988	A
4781685	Lehmann et al.	Nov 1988	A
4781695	Dalton	Nov 1988	A
4784646	Feingold	Nov 1988	A
4802885	Weeks et al.	Feb 1989	A
4804054	Howson et al.	Feb 1989	A
4820273	Reinicke	Apr 1989	A
4822341	Colone	Apr 1989	A
4840615	Hancock et al.	Jun 1989	A
4848346	Crawford	Jul 1989	A
4857053	Dalton	Aug 1989	A
4861341	Woodburn	Aug 1989	A
4863470	Carter	Sep 1989	A
4886501	Johnston et al.	Dec 1989	A
4886502	Poirier et al.	Dec 1989	A
4892518	Cupp et al.	Jan 1990	A
4897081	Poirier et al.	Jan 1990	A
4904241	Bark	Feb 1990	A
4905709	Bieganski et al.	Mar 1990	A
4908029	Bark et al.	Mar 1990	A
4909250	Smith	Mar 1990	A
4915690	Cone et al.	Apr 1990	A
4928298	Tanaka	May 1990	A
4929236	Sampson	May 1990	A
4955861	Enegren et al.	Sep 1990	A
4961267	Herzog	Oct 1990	A
4963133	Whipple	Oct 1990	A
4966583	Debbas	Oct 1990	A
4973319	Melsky	Nov 1990	A
4983162	Metais et al.	Jan 1991	A
5002735	Alberhasky et al.	Mar 1991	A
5009391	Steigerwald	Apr 1991	A
5009644	McDonald	Apr 1991	A
5013298	Moden et al.	May 1991	A
5041098	Loiterman et al.	Aug 1991	A
5044955	Jagmin	Sep 1991	A
5045060	Melsky et al.	Sep 1991	A
5045064	Idriss	Sep 1991	A
5053013	Ensminger et al.	Oct 1991	A
5059186	Yamamoto et al.	Oct 1991	A
5069206	Crosbie	Dec 1991	A
5084015	Moriuchi	Jan 1992	A
5085216	Henley, Jr. et al.	Feb 1992	A
5090066	Schoepe et al.	Feb 1992	A
5092849	Sampson	Mar 1992	A
5108317	Beinhaur et al.	Apr 1992	A
5108377	Cone et al.	Apr 1992	A
5112301	Fenton, Jr. et al.	May 1992	A
5112303	Pudenz et al.	May 1992	A
5129891	Young	Jul 1992	A
5137529	Watson et al.	Aug 1992	A
5147483	Melsky et al.	Sep 1992	A
5152753	Laguette et al.	Oct 1992	A
5156600	Young	Oct 1992	A
5158547	Doan et al.	Oct 1992	A
5167629	Vertenstein et al.	Dec 1992	A
5167633	Mann et al.	Dec 1992	A
5167638	Felix et al.	Dec 1992	A
5169393	Moorehead et al.	Dec 1992	A
5171228	McDonald	Dec 1992	A
5176653	Metals	Jan 1993	A
5176662	Bartholomew et al.	Jan 1993	A
5178612	Fenton, Jr.	Jan 1993	A
5185003	Brethauer	Feb 1993	A
5189690	Samuel	Feb 1993	A
5193106	DeSena	Mar 1993	A
5195122	Fabian	Mar 1993	A
5195123	Clement	Mar 1993	A
5201715	Masters	Apr 1993	A
5201722	Moorehead et al.	Apr 1993	A
5203771	Melker et al.	Apr 1993	A
5203777	Lee	Apr 1993	A
5205834	Moorehead et al.	Apr 1993	A
5213574	Tucker	May 1993	A
5215537	Lynn et al.	Jun 1993	A
5222499	Allen et al.	Jun 1993	A
D337637	Tucker	Jul 1993	S
5224938	Fenton, Jr.	Jul 1993	A
5242415	Kantrowitz et al.	Sep 1993	A
5246462	Bekki et al.	Sep 1993	A
5249598	Schmidt	Oct 1993	A
5263930	Ensminger	Nov 1993	A
5281205	McPherson	Jan 1994	A
5290263	Wigness et al.	Mar 1994	A
5295658	Atkinson et al.	Mar 1994	A
5299253	Wessels	Mar 1994	A
5300048	Drewes, Jr. et al.	Apr 1994	A
5309863	Leeb, Jr.	May 1994	A
5312337	Flaherty et al.	May 1994	A
5318545	Tucker	Jun 1994	A
5320100	Herweck et al.	Jun 1994	A
5328480	Melker et al.	Jul 1994	A
5332398	Miller et al.	Jul 1994	A
5336194	Polaschegg et al.	Aug 1994	A
5338398	Szwejkowski et al.	Aug 1994	A
5350360	Ensminger et al.	Sep 1994	A
5352204	Ensminger	Oct 1994	A
5360407	Leonard et al.	Nov 1994	A
5383223	Inokuchi	Jan 1995	A
5383233	Russell	Jan 1995	A
5383585	Weiss	Jan 1995	A
5383858	Reilly et al.	Jan 1995	A
D355240	Gladfelter et al.	Feb 1995	S
5387192	Glantz et al.	Feb 1995	A
5394457	Leibinger et al.	Feb 1995	A
5395324	Hinrichs et al.	Mar 1995	A
5396925	Poli	Mar 1995	A
5397329	Allen	Mar 1995	A
5399168	Wadsworth, Jr. et al.	Mar 1995	A
5405402	Dye et al.	Apr 1995	A
5417656	Ensminger et al.	May 1995	A
5421814	Geary	Jun 1995	A
5423334	Jordan	Jun 1995	A
5425762	Muller	Jun 1995	A
5453097	Paradis	Sep 1995	A
5456698	Byland et al.	Oct 1995	A
5476451	Ensminger et al.	Dec 1995	A
5476460	Montalvo	Dec 1995	A
5476880	Cooke et al.	Dec 1995	A
5484402	Saravia et al.	Jan 1996	A
5503630	Ensminger et al.	Apr 1996	A
5507813	Dowd et al.	Apr 1996	A
5509805	Jagmin	Apr 1996	A
5513637	Twiss et al.	May 1996	A
5514103	Srisathapat et al.	May 1996	A
5520632	Leveen et al.	May 1996	A
5520643	Ensminger et al.	May 1996	A
5527277	Ensminger et al.	Jun 1996	A
5527278	Ensminger et al.	Jun 1996	A
5527307	Srisathapat et al.	Jun 1996	A
5531684	Ensminger et al.	Jul 1996	A
5542923	Ensminger et al.	Aug 1996	A
5545143	Fischell	Aug 1996	A
5554117	Ensminger et al.	Sep 1996	A
5556381	Ensminger et al.	Sep 1996	A
5558641	Glantz et al.	Sep 1996	A
5562617	Finch, Jr. et al.	Oct 1996	A
5562618	Cai et al.	Oct 1996	A
5575770	Melsky et al.	Nov 1996	A
5593434	Williams	Jan 1997	A
5607393	Ensminger et al.	Mar 1997	A
5607407	Tolkoff et al.	Mar 1997	A
5613945	Cai et al.	Mar 1997	A
5620419	Lui et al.	Apr 1997	A
5632729	Cai et al.	May 1997	A
5637102	Tolkoff et al.	Jun 1997	A
5638832	Singer et al.	Jun 1997	A
5647855	Trooskin	Jul 1997	A
RE35601	Eckenhoff	Sep 1997	E
5662600	Watson et al.	Sep 1997	A
5662612	Niehoff	Sep 1997	A
5662616	Bousquet	Sep 1997	A
5676146	Scarborough	Oct 1997	A
5695490	Flaherty et al.	Dec 1997	A
5702128	Maxim et al.	Dec 1997	A
5702363	Flaherty	Dec 1997	A
5704915	Melsky et al.	Jan 1998	A
5707357	Mikhail et al.	Jan 1998	A
5709668	Wacks	Jan 1998	A
5713844	Peyman	Feb 1998	A
5713858	Heruth et al.	Feb 1998	A
5713859	Finch, Jr. et al.	Feb 1998	A
5718382	Jaeger	Feb 1998	A
5718682	Tucker	Feb 1998	A
5725507	Petrick	Mar 1998	A
5733336	Neuenfeldt et al.	Mar 1998	A
5733400	Gore et al.	Mar 1998	A
5741228	Lambrecht et al.	Apr 1998	A
5743873	Cai et al.	Apr 1998	A
5743891	Tolkoff et al.	Apr 1998	A
5746460	Marohl et al.	May 1998	A
5758667	Slettenmark	Jun 1998	A
5769823	Otto	Jun 1998	A
5773552	Hutchings et al.	Jun 1998	A
5776188	Shepherd et al.	Jul 1998	A
5792104	Speckman et al.	Aug 1998	A
5792116	Berg et al.	Aug 1998	A
5797886	Roth et al.	Aug 1998	A
5810789	Powers et al.	Sep 1998	A
5814016	Valley et al.	Sep 1998	A
5824071	Nelson et al.	Oct 1998	A
5830172	Leveen et al.	Nov 1998	A
5833654	Powers et al.	Nov 1998	A
5835563	Navab et al.	Nov 1998	A
5836935	Ashton et al.	Nov 1998	A
5840063	Flaherty	Nov 1998	A
5843069	Butler et al.	Dec 1998	A
5848989	Villani	Dec 1998	A
5853394	Tolkoff et al.	Dec 1998	A
5868702	Stevens et al.	Feb 1999	A
5879322	Lattin et al.	Mar 1999	A
5882341	Bousquet	Mar 1999	A
5882353	VanBeek et al.	Mar 1999	A
5895424	Steele, Sr. et al.	Apr 1999	A
5897528	Schultz	Apr 1999	A
5899856	Schoendorfer et al.	May 1999	A
5904934	Maruyama et al.	May 1999	A
5906596	Tallarida	May 1999	A
5908413	Lange et al.	Jun 1999	A
5908414	Otto et al.	Jun 1999	A
5911706	Estabrook et al.	Jun 1999	A
5913998	Butler et al.	Jun 1999	A
5916263	Goicoechea et al.	Jun 1999	A
5919160	Sanfilippo, II	Jul 1999	A
5925017	Kriesel et al.	Jul 1999	A
5925030	Gross et al.	Jul 1999	A
5927345	Samson	Jul 1999	A
5928197	Niehoff	Jul 1999	A
5928744	Heilmann et al.	Jul 1999	A
5931829	Burbank et al.	Aug 1999	A
5941856	Kovacs et al.	Aug 1999	A
5944023	Johnson et al.	Aug 1999	A
5944688	Lois	Aug 1999	A
5944698	Fischer et al.	Aug 1999	A
5944712	Frassica et al.	Aug 1999	A
D413672	Fogarty	Sep 1999	S
5947953	Ash et al.	Sep 1999	A
5951512	Dalton	Sep 1999	A
5951522	Rosato et al.	Sep 1999	A
5951929	Wilson	Sep 1999	A
5954687	Baudino	Sep 1999	A
5954691	Prosl	Sep 1999	A
5957890	Mann et al.	Sep 1999	A
5961497	Larkin	Oct 1999	A
5968011	Larsen et al.	Oct 1999	A
5970162	Kawashima	Oct 1999	A
5989216	Johnson et al.	Nov 1999	A
5989239	Finch et al.	Nov 1999	A
5989641	Oulie	Nov 1999	A
5997524	Burbank et al.	Dec 1999	A
6007516	Burbank et al.	Dec 1999	A
6013051	Nelson	Jan 2000	A
6013058	Prosl et al.	Jan 2000	A
6017331	Watts et al.	Jan 2000	A
6022335	Ramadan	Feb 2000	A
6033389	Cornish	Mar 2000	A
6039712	Fogarty et al.	Mar 2000	A
6056717	Finch et al.	May 2000	A
6077756	Lin et al.	Jun 2000	A
6086555	Eliasen et al.	Jul 2000	A
6090066	Schnell	Jul 2000	A
6099508	Bousquet	Aug 2000	A
6102884	Squitieri	Aug 2000	A
6113572	Gailey et al.	Sep 2000	A
6120492	Finch et al.	Sep 2000	A
6152909	Bagaoisan et al.	Nov 2000	A
6161033	Kuhn	Dec 2000	A
6171198	Troncoso et al.	Jan 2001	B1
6171298	Matsuura et al.	Jan 2001	B1
6186982	Gross et al.	Feb 2001	B1
6190352	Haarala et al.	Feb 2001	B1
6193684	Burbank et al.	Feb 2001	B1
6198807	DeSena	Mar 2001	B1
6200338	Solomon et al.	Mar 2001	B1
6203570	Baeke	Mar 2001	B1
6210366	Sanfilippo, II	Apr 2001	B1
6213973	Eliasen et al.	Apr 2001	B1
6228088	Miller et al.	May 2001	B1
6251059	Apple et al.	Jun 2001	B1
D445175	Bertheas	Jul 2001	S
6261259	Bell	Jul 2001	B1
6269148	Jessop et al.	Jul 2001	B1
6272370	Gillies et al.	Aug 2001	B1
6287293	Jones et al.	Sep 2001	B1
6290677	Arai et al.	Sep 2001	B1
6305413	Fischer et al.	Oct 2001	B1
6306124	Jones et al.	Oct 2001	B1
D450115	Bertheas	Nov 2001	S
6332874	Eliasen et al.	Dec 2001	B1
6355021	Nielsen et al.	Mar 2002	B1
6356782	Sirimanne et al.	Mar 2002	B1
6361557	Gittings et al.	Mar 2002	B1
6398764	Finch, Jr. et al.	Jun 2002	B1
6419680	Cosman et al.	Jul 2002	B1
6450937	Mercereau et al.	Sep 2002	B1
6473638	Ferek-Petric	Oct 2002	B2
6475516	DiCosmo et al.	Nov 2002	B2
6478783	Moorehead	Nov 2002	B1
6482217	Pintor et al.	Nov 2002	B1
6494867	Elver et al.	Dec 2002	B1
6497062	Koopman et al.	Dec 2002	B1
6500155	Sasso	Dec 2002	B2
6503228	Li et al.	Jan 2003	B1
6527754	Tallarida et al.	Mar 2003	B1
6537255	Raines	Mar 2003	B1
RE38074	Recinella et al.	Apr 2003	E
6572583	Olsen et al.	Jun 2003	B1
6582418	Verbeek et al.	Jun 2003	B1
6592571	Verbeek et al.	Jul 2003	B1
6610031	Chin	Aug 2003	B1
6613002	Clark et al.	Sep 2003	B1
6613662	Wark et al.	Sep 2003	B2
6626936	Stinson	Sep 2003	B2
6629950	Levin	Oct 2003	B1
6632217	Harper et al.	Oct 2003	B2
6652486	Bialecki et al.	Nov 2003	B2
6652503	Bradley	Nov 2003	B1
6663646	Shah	Dec 2003	B1
6676633	Smith et al.	Jan 2004	B2
6697664	Kienzle, III et al.	Feb 2004	B2
6705316	Blythe et al.	Mar 2004	B2
6719721	Okazaki et al.	Apr 2004	B1
6719739	Verbeek et al.	Apr 2004	B2
6726063	Stull et al.	Apr 2004	B2
6738531	Funahashi	May 2004	B1
6755842	Kanner et al.	Jun 2004	B2
6758841	Haarala et al.	Jul 2004	B2
6767356	Kanner et al.	Jul 2004	B2
6784783	Scoggin et al.	Aug 2004	B2
6808738	DiTizio et al.	Oct 2004	B2
6826257	Sayre et al.	Nov 2004	B2
6852106	Watson et al.	Feb 2005	B2
6856055	Michaels et al.	Feb 2005	B2
6878136	Fleury et al.	Apr 2005	B2
6878137	Benchetrit	Apr 2005	B2
6929631	Brugger et al.	Aug 2005	B1
6949084	Marggi et al.	Sep 2005	B2
6962577	Tallarida et al.	Nov 2005	B2
6962580	Adams et al.	Nov 2005	B2
6994315	Ryan et al.	Feb 2006	B2
6997914	Smith et al.	Feb 2006	B2
7008377	Beane et al.	Mar 2006	B2
7008412	Maginot	Mar 2006	B2
7016456	Basu et al.	Mar 2006	B2
7018361	Gillespie, Jr. et al.	Mar 2006	B2
7033339	Lynn	Apr 2006	B1
7044942	Jolly et al.	May 2006	B2
7056316	Burbank et al.	Jun 2006	B1
7070591	Adams et al.	Jul 2006	B2
7072704	Bucholz	Jul 2006	B2
7074232	Kanner et al.	Jul 2006	B2
7076305	Imran et al.	Jul 2006	B2
7083593	Stultz	Aug 2006	B2
7108686	Burke et al.	Sep 2006	B2
7123690	Brown et al.	Oct 2006	B1
7127040	Sayre et al.	Oct 2006	B2
7131962	Estabrook et al.	Nov 2006	B1
7140769	Kay	Nov 2006	B2
7191011	Cantlon	Mar 2007	B2
7198631	Kanner et al.	Apr 2007	B2
7214207	Lynch et al.	May 2007	B2
7214215	Heinzerling et al.	May 2007	B2
7223257	Shubayev et al.	May 2007	B2
7229417	Foerster et al.	Jun 2007	B2
7235067	Morris et al.	Jun 2007	B2
D546440	Burnside	Jul 2007	S
7242982	Singhal et al.	Jul 2007	B2
7248668	Galkin	Jul 2007	B2
7252469	Zaluzec et al.	Aug 2007	B2
7252649	Sherry	Aug 2007	B2
7261705	Edoga et al.	Aug 2007	B2
D554253	Kornerup	Oct 2007	S
7275682	Excoffier et al.	Oct 2007	B2
7276075	Callas et al.	Oct 2007	B1
D556153	Burnside	Nov 2007	S
7306579	Fujii	Dec 2007	B2
7311702	Tallarida et al.	Dec 2007	B2
7318816	Bobroff et al.	Jan 2008	B2
7318818	Yashiro et al.	Jan 2008	B2
7322953	Redinger	Jan 2008	B2
D562442	Blateri	Feb 2008	S
D562443	Zinn et al.	Feb 2008	S
7331130	Schweikert	Feb 2008	B2
7331948	Skarda	Feb 2008	B2
7333013	Berger	Feb 2008	B2
D564449	Dewberry	Mar 2008	S
7347838	Kulli	Mar 2008	B2
7347843	Adams et al.	Mar 2008	B2
7351233	Parks	Apr 2008	B2
7377915	Rasmussen et al.	May 2008	B2
D574950	Zawacki et al.	Aug 2008	S
7413564	Morris et al.	Aug 2008	B2
D578203	Bizup	Oct 2008	S
7445614	Bunodiere et al.	Nov 2008	B2
D582032	Bizup et al.	Dec 2008	S
7465847	Fabian	Dec 2008	B2
7485148	Wozencroft et al.	Feb 2009	B2
7552853	Mas et al.	Jun 2009	B2
7553298	Hunt et al.	Jun 2009	B2
D595892	Smith et al.	Jul 2009	S
7563025	Kay	Jul 2009	B2
D612479	Zawacki et al.	Mar 2010	S
7713251	Tallarida et al.	May 2010	B2
7785302	Powers	Aug 2010	B2
7803143	Tallarida et al.	Sep 2010	B2
7806888	Frassica	Oct 2010	B2
7811266	Eliasen	Oct 2010	B2
D629503	Caffey et al.	Dec 2010	S
D634840	Lombardi, III et al.	Mar 2011	S
7909804	Stats	Mar 2011	B2
7947022	Amin et al.	May 2011	B2
7959615	Stats et al.	Jun 2011	B2
8021324	Bizup et al.	Sep 2011	B2
8025639	Powers et al.	Sep 2011	B2
8029482	Maniar et al.	Oct 2011	B2
8075536	Gray et al.	Dec 2011	B2
8092435	Beling et al.	Jan 2012	B2
8147455	Butts et al.	Apr 2012	B2
8172894	Schmid et al.	May 2012	B2
8172896	McNamara et al.	May 2012	B2
8177762	Beasley et al.	May 2012	B2
8182453	Eliasen	May 2012	B2
8197454	Mann et al.	Jun 2012	B2
8202259	Evans et al.	Jun 2012	B2
8257325	Schweikert et al.	Sep 2012	B2
D676955	Orome	Feb 2013	S
8377034	Tallarida et al.	Feb 2013	B2
8382723	Powers et al.	Feb 2013	B2
8382724	Maniar et al.	Feb 2013	B2
8409153	Tallarida et al.	Apr 2013	B2
8475417	Powers et al.	Jul 2013	B2
8545460	Beasley et al.	Oct 2013	B2
8585663	Powers et al.	Nov 2013	B2
8603052	Powers et al.	Dec 2013	B2
8608713	Beasley et al.	Dec 2013	B2
8641676	Butts et al.	Feb 2014	B2
8641688	Powers et al.	Feb 2014	B2
8805478	Powers et al.	Aug 2014	B2
20010016717	Haarala et al.	Aug 2001	A1
20010047165	Makower et al.	Nov 2001	A1
20010051766	Gazdzinski	Dec 2001	A1
20010053889	Marggi et al.	Dec 2001	A1
20010056266	Tallarida et al.	Dec 2001	A1
20020013557	Sherry	Jan 2002	A1
20020052576	Massengale	May 2002	A1
20020055715	Young et al.	May 2002	A1
20020095205	Edwin et al.	Jul 2002	A1
20020121530	Socier	Sep 2002	A1
20020138068	Watson et al.	Sep 2002	A1
20020169418	Menzi et al.	Nov 2002	A1
20020173769	Gray et al.	Nov 2002	A1
20020173772	Olsen	Nov 2002	A1
20020183846	Kuslich et al.	Dec 2002	A1
20020188282	Greenberg	Dec 2002	A1
20030028173	Forsberg	Feb 2003	A1
20030093029	McGuckin et al.	May 2003	A1
20030109856	Sherry	Jun 2003	A1
20030130627	Smith et al.	Jul 2003	A1
20030139812	Garcia et al.	Jul 2003	A1
20030141477	Miller	Jul 2003	A1
20030181878	Tallarida et al.	Sep 2003	A1
20030191452	Meglin et al.	Oct 2003	A1
20030208184	Burke et al.	Nov 2003	A1
20030216694	Tollini	Nov 2003	A1
20030217659	Yamamoto et al.	Nov 2003	A1
20040006316	Patton	Jan 2004	A1
20040020462	Sauler et al.	Feb 2004	A1
20040020492	Dubrul et al.	Feb 2004	A1
20040044306	Lynch et al.	Mar 2004	A1
20040054352	Adams et al.	Mar 2004	A1
20040056266	Suh et al.	Mar 2004	A1
20040064110	Forsell	Apr 2004	A1
20040073196	Adams et al.	Apr 2004	A1
20040078000	Borchard et al.	Apr 2004	A1
20040086568	Ditizio et al.	May 2004	A1
20040087877	Besz et al.	May 2004	A1
20040087885	Kawano et al.	May 2004	A1
20040106878	Skujins et al.	Jun 2004	A1
20040106891	Langan et al.	Jun 2004	A1
20040106942	Taylor et al.	Jun 2004	A1
20040133173	Edoga et al.	Jul 2004	A1
20040156472	Galkin	Aug 2004	A1
20040157952	Soffiati et al.	Aug 2004	A1
20040158207	Hunn et al.	Aug 2004	A1
20040167543	Mazzocchi et al.	Aug 2004	A1
20040176743	Morris et al.	Sep 2004	A1
20040186444	Daly et al.	Sep 2004	A1
20040199129	DiMatteo	Oct 2004	A1
20040199220	Cantlon	Oct 2004	A1
20040204692	Eliasen	Oct 2004	A1
20040204759	Blom et al.	Oct 2004	A1
20040225254	Tanaka et al.	Nov 2004	A1
20040254536	Conlon et al.	Dec 2004	A1
20040254537	Conlon et al.	Dec 2004	A1
20050010176	Dikeman et al.	Jan 2005	A1
20050010286	Vijay	Jan 2005	A1
20050027234	Waggoner et al.	Feb 2005	A1
20050027261	Weaver et al.	Feb 2005	A1
20050038390	Fago et al.	Feb 2005	A1
20050049553	Triplett et al.	Mar 2005	A1
20050070875	Kulessa	Mar 2005	A1
20050075614	Bunodiere et al.	Apr 2005	A1
20050080401	Peavey	Apr 2005	A1
20050085778	Parks	Apr 2005	A1
20050113806	De Carvalho et al.	May 2005	A1
20050124980	Sanders	Jun 2005	A1
20050131352	Conlon et al.	Jun 2005	A1
20050148866	Gunderson	Jul 2005	A1
20050148869	Masuda	Jul 2005	A1
20050148956	Conlon et al.	Jul 2005	A1
20050148957	Girard et al.	Jul 2005	A1
20050152841	Sayre et al.	Jul 2005	A1
20050171502	Daly et al.	Aug 2005	A1
20050182857	Kong	Aug 2005	A1
20050209573	Brugger et al.	Sep 2005	A1
20050215874	Wang et al.	Sep 2005	A1
20050241203	Lizotte et al.	Nov 2005	A1
20050256451	Adams et al.	Nov 2005	A1
20050256500	Fujii	Nov 2005	A1
20050277899	Conlon et al.	Dec 2005	A1
20050283119	Uth et al.	Dec 2005	A1
20060009788	Freeman et al.	Jan 2006	A1
20060017341	Hahn et al.	Jan 2006	A1
20060084929	Eliasen	Apr 2006	A1
20060089619	Ginggen	Apr 2006	A1
20060100592	Eliasen	May 2006	A1
20060116648	Hamatake	Jun 2006	A1
20060171980	Helmus et al.	Aug 2006	A1
20060173410	Moberg et al.	Aug 2006	A1
20060173424	Conlon	Aug 2006	A1
20060178647	Stats	Aug 2006	A1
20060178648	Barron et al.	Aug 2006	A1
20060184141	Smith et al.	Aug 2006	A1
20060184142	Schon et al.	Aug 2006	A1
20060217359	Wentworth et al.	Sep 2006	A1
20060217659	Patton	Sep 2006	A1
20060224128	Lurvey et al.	Oct 2006	A1
20060224129	Beasley et al.	Oct 2006	A1
20060224235	Rucker	Oct 2006	A1
20060241465	Huennekens et al.	Oct 2006	A1
20060247584	Sheetz et al.	Nov 2006	A1
20060253076	Butts et al.	Nov 2006	A1
20060264898	Beasley et al.	Nov 2006	A1
20070003603	Karandikar et al.	Jan 2007	A1
20070007839	Lin	Jan 2007	A1
20070010881	Soye et al.	Jan 2007	A1
20070016162	Burbank et al.	Jan 2007	A1
20070049806	Adams et al.	Mar 2007	A1
20070049876	Patton	Mar 2007	A1
20070055290	Lober	Mar 2007	A1
20070073250	Schneiter	Mar 2007	A1
20070078391	Wortley et al.	Apr 2007	A1
20070078416	Eliasen	Apr 2007	A1
20070078432	Halseth et al.	Apr 2007	A1
20070083111	Hossack et al.	Apr 2007	A1
20070083156	Muto et al.	Apr 2007	A1
20070100302	Dicarlo et al.	May 2007	A1
20070112332	Harding et al.	May 2007	A1
20070120683	Flippen et al.	May 2007	A1
20070135775	Edoga et al.	Jun 2007	A1
20070149920	Michels et al.	Jun 2007	A1
20070149921	Michels et al.	Jun 2007	A1
20070149947	Byrum	Jun 2007	A1
20070161958	Glenn	Jul 2007	A1
20070179456	Glenn	Aug 2007	A1
20070185462	Byrum	Aug 2007	A1
20070191773	Wojcik	Aug 2007	A1
20070207335	Karandikar et al.	Sep 2007	A1
20070208313	Conlon et al.	Sep 2007	A1
20070219510	Zinn et al.	Sep 2007	A1
20070233017	Zinn et al.	Oct 2007	A1
20070233018	Bizup et al.	Oct 2007	A1
20070255234	Haase et al.	Nov 2007	A1
20070270691	Bailey et al.	Nov 2007	A1
20070270770	Bizup	Nov 2007	A1
20070276344	Bizup et al.	Nov 2007	A1
20070276355	Nielsen et al.	Nov 2007	A1
20070282308	Bell	Dec 2007	A1
20070293800	McMaken et al.	Dec 2007	A1
20070299408	Alferness et al.	Dec 2007	A1
20080004642	Birk et al.	Jan 2008	A1
20080008654	Clarke et al.	Jan 2008	A1
20080015701	Garcia et al.	Jan 2008	A1
20080039820	Sommers et al.	Feb 2008	A1
20080048855	Berger	Feb 2008	A1
20080108949	Beasley et al.	May 2008	A1
20080114308	di Palma et al.	May 2008	A1
20080133265	Silkaitis et al.	Jun 2008	A1
20080137923	Spahn	Jun 2008	A1
20080138387	Machiraju	Jun 2008	A1
20080140025	Sheetz et al.	Jun 2008	A1
20080208236	Hobbs et al.	Aug 2008	A1
20080281279	Hoendervoogt et al.	Nov 2008	A1
20080319398	Bizup	Dec 2008	A1
20080319399	Schweikert et al.	Dec 2008	A1
20080319405	Bizup	Dec 2008	A1
20090024024	Zinn	Jan 2009	A1
20090024098	Bizup et al.	Jan 2009	A1
20090035582	Nakatani et al.	Feb 2009	A1
20090118683	Hanson et al.	May 2009	A1
20090156928	Evans et al.	Jun 2009	A1
20090204072	Amin et al.	Aug 2009	A1
20090204074	Powers et al.	Aug 2009	A1
20090216216	Powers et al.	Aug 2009	A1
20090221976	Linden	Sep 2009	A1
20090227862	Smith et al.	Sep 2009	A1
20090227951	Powers et al.	Sep 2009	A1
20090227964	DiCarlo et al.	Sep 2009	A1
20090264901	Franklin et al.	Oct 2009	A1
20090322541	Jones et al.	Dec 2009	A1
20100010339	Smith et al.	Jan 2010	A1
20100042073	Oster et al.	Feb 2010	A1
20100063451	Gray et al.	Mar 2010	A1
20100069743	Sheetz et al.	Mar 2010	A1
20100121283	Hamatake et al.	May 2010	A1
20100211026	Sheetz et al.	Aug 2010	A2
20100268165	Maniar et al.	Oct 2010	A1
20100268174	Steinke et al.	Oct 2010	A1
20110021922	Berard-Anderson et al.	Jan 2011	A1
20110092921	Beling et al.	Apr 2011	A1
20110118677	Wiley et al.	May 2011	A1
20110183712	Eckstein et al.	Jul 2011	A1
20110213700	Sant'Anselmo	Sep 2011	A1
20110275930	Jho et al.	Nov 2011	A1
20110276015	Powers et al.	Nov 2011	A1
20110288502	Hibdon et al.	Nov 2011	A1
20110311337	Amin et al.	Dec 2011	A1
20120018073	Maniar et al.	Jan 2012	A1
20120065622	Cornish et al.	Mar 2012	A1
20120078201	Mikami	Mar 2012	A1
20120191071	Butts et al.	Jul 2012	A1
20120226244	Beasley et al.	Sep 2012	A1
20120302969	Wiley et al.	Nov 2012	A1
20130165773	Powers et al.	Jun 2013	A1
20130172733	Maniar et al.	Jul 2013	A1
20130225990	Powers et al.	Aug 2013	A1
20130225991	Powers	Aug 2013	A1
20130245574	Powers et al.	Sep 2013	A1
20130338494	Wiley et al.	Dec 2013	A1
20140081219	Powers et al.	Mar 2014	A1
20140100534	Beasley et al.	Apr 2014	A1
20140107619	Butts et al.	Apr 2014	A1
20140330118	Powers et al.	Nov 2014	A1

Foreign Referenced Citations (128)

Number	Date	Country
2008299945	Mar 2009	AU
2663853	Apr 2008	CA
2692142	Dec 2008	CA
2693972	Jan 2009	CA
102421469	Apr 2012	CN
102612343	Jul 2012	CN
3618390	Nov 1987	DE
3720414	Dec 1987	DE
10346470	May 2005	DE
0128525	Dec 1984	EP
0134745	Mar 1985	EP
0343910	Nov 1989	EP
0366814	May 1990	EP
0239244	Sep 1991	EP
0534782	Mar 1993	EP
0619101	Oct 1994	EP
1635899	Mar 2006	EP
2006019101	Dec 2006	EP
1858565	Nov 2007	EP
1874393	Jan 2008	EP
1896117	Mar 2008	EP
1998842	Dec 2008	EP
2004272	Dec 2008	EP
2018209	Jan 2009	EP
2081634	Jul 2009	EP
2164559	Mar 2010	EP
2167182	Mar 2010	EP
2180915	May 2010	EP
2190517	Jun 2010	EP
2308547	Apr 2011	EP
2320974	May 2011	EP
2324878	May 2011	EP
2324879	May 2011	EP
2324880	May 2011	EP
2365838	Sep 2011	EP
2571563	Mar 2013	EP
2601999	Jun 2013	EP
2324879	Jan 2014	EP
1509165	Jan 1968	FR
2508008	Dec 1982	FR
2809315	Nov 2001	FR
178998	May 1922	GB
749942	Jun 1956	GB
966137	Aug 1964	GB
1559140	Jan 1980	GB
2102398	Feb 1983	GB
2191701	Dec 1987	GB
2350352	Nov 2000	GB
62155857	Jul 1987	JP
62281966	Dec 1987	JP
6296633	Oct 1994	JP
2000-079168	Mar 2000	JP
2002500076	Jan 2002	JP
2003-510136	Mar 2003	JP
2004-350937	Dec 2004	JP
2006025948	Feb 2006	JP
2012-523284	Oct 2012	JP
2013-510652	Mar 2013	JP
2013-526376	Jun 2013	JP
8600213	Jan 1986	WO
8911309	Nov 1989	WO
9001958	Mar 1990	WO
9206732	Apr 1992	WO
9300945	Jan 1993	WO
9305730	Apr 1993	WO
9308986	May 1993	WO
9515194	Jun 1995	WO
9516480	Jun 1995	WO
9701370	Jan 1997	WO
9706845	Feb 1997	WO
9711726	Apr 1997	WO
9723255	Jul 1997	WO
9726931	Jul 1997	WO
9817337	Apr 1998	WO
9818506	May 1998	WO
9831417	Jul 1998	WO
9934859	Jul 1999	WO
9938553	Aug 1999	WO
9942166	Aug 1999	WO
0012171	Mar 2000	WO
0016844	Mar 2000	WO
0033901	Jun 2000	WO
0123023	Apr 2001	WO
0160444	Aug 2001	WO
0247549	Jun 2002	WO
03084832	Oct 2003	WO
03090509	Nov 2003	WO
2004004800	Jan 2004	WO
2004028611	Apr 2004	WO
2004071555	Aug 2004	WO
2004091434	Oct 2004	WO
2005037055	Apr 2005	WO
2005068009	Jul 2005	WO
2006078915	Jul 2006	WO
2006096686	Sep 2006	WO
2006116438	Nov 2006	WO
2006116613	Nov 2006	WO
2006130133	Dec 2006	WO
2006134100	Dec 2006	WO
2007041471	Apr 2007	WO
2007079024	Jul 2007	WO
2007092210	Aug 2007	WO
2007094898	Aug 2007	WO
2007098771	Sep 2007	WO
2007109164	Sep 2007	WO
2007126645	Nov 2007	WO
2007136538	Nov 2007	WO
2008008126	Jan 2008	WO
2008019236	Feb 2008	WO
2008048361	Apr 2008	WO
2008062173	May 2008	WO
2008063226	May 2008	WO
2008147760	Dec 2008	WO
2008157763	Dec 2008	WO
2009002839	Dec 2008	WO
2009012385	Jan 2009	WO
2009012395	Jan 2009	WO
2009035582	Mar 2009	WO
2009046439	Apr 2009	WO
2009046725	Apr 2009	WO
2009108669	Sep 2009	WO
2010030351	Mar 2010	WO
2010062633	Jun 2010	WO
2010118144	Oct 2010	WO
2011046604	Apr 2011	WO
2011062750	May 2011	WO
2011146649	Nov 2011	WO
2014031763	Feb 2014	WO

Non-Patent Literature Citations (321)

Entry
LAP-BAND® System Access Port Fill Guide I, “9.75/10.0 cm LAP-BAND System vs. 11 cm LAP-BAND System: For Product Manufactured Prior to Jul. 2001” BioEnterics Corporation.
Leslie et al., “A New Simple Power Injector,” Am J Roentgenol 128: 381-384, Mar. 1977.
MedComp “PortCT Technology”, display at SIR Conference (Mar. 2006), Toronto, Canada.
Navilyst Medical, Implantable Ports with PASV® Valve Technology, Product Overview, <<http://www.navilystmedical.com/Products/index.cfm/9>> last accessed Jun. 4, 2012.
Nucleus Cochlear Implant Systems; User Manual for the ESPrit 3G speech processor and accessories, Issue 2, Dec. 2001 http://www.cochlearamericas.com/PDFs/UserManualSprint.pdf.
Oct. 22, 2009 Declaration of Kelly Christian, Director of Product Development at BARD Access Systems, Inc, in support of and depicting a product on the market by Quinton Company approximately ten years prior to Oct. 22, 2009, 1 page.
PCT/US1999/028695 filed Dec. 3, 1999 International Preliminary Examination Report dated Apr. 21, 2001.
PCT/US1999/028695 filed Dec. 3, 1999 Search Report dated Apr. 11, 2000.
PCT/US2006/008022 filed Mar. 6, 2006 International Preliminary Report on Patentability dated Sep. 12, 2007.
PCT/US2006/008022 filed Mar. 6, 2006 Search Report dated Jul. 5, 2006.
PCT/US2006/008022 filed Mar. 6, 2006 Written Opinion dated Apr. 9, 2007.
PCT/US2006/008022 filed Mar. 6, 2006 Written Opinion dated Jul. 5, 2006.
PCT/US2006/015695 filed Apr. 25, 2006 Partial Search Report dated Sep. 29, 2006.
PCT/US2006/015695 filed Apr. 25, 2006 Search Report dated Jan. 11, 2007.
PCT/US2006/015695 filed Apr. 25, 2006 Written Opinion dated Jan. 11, 2007.
PCT/US2006/016056 filed Apr. 27, 2006 International Preliminary Report on Patentability dated Oct. 30, 2007.
PCT/US2006/016056 filed Apr. 27, 2006 Search Report dated Sep. 20, 2006.
PCT/US2006/016056 filed Apr. 27, 2006 Written Opinion dated Oct. 27, 2007.
PCT/US2006/016056 filed Apr. 27, 2006 Written Opinion dated Sep. 20, 2006.
PCT/US2006/049007 filed Dec. 21, 2006 International Preliminary Report on Patentability dated Jul. 1, 2008.
PCT/US2006/049007 filed Dec. 21, 2006 Search Report dated Oct. 1, 2007.
PCT/US2006/049007 filed Dec. 21, 2006 Written Opinion dated Oct. 1, 2007.
PCT/US2007/006776 filed Mar. 19, 2007 International Preliminary Report on Patentability dated Jan. 2, 2009.
PCT/US2007/006776 filed Mar. 19, 2007 Search Report, dated Dec. 18, 2007.
PCT/US2007/006776 filed Mar. 19, 2007 Written opinion, dated Dec. 18, 2007.
PCT/US2007/011015 dated May 7, 2007 Written Opinion dated Jun. 10, 2008.
PCT/US2007/011015 filed May 7, 2007 International Preliminary Report on Patentability dated Oct. 29, 2008.
PCT/US2007/011015 filed May 7, 2007 Search Report dated Jun. 10, 2008.
PCT/US2007/011456 filed May 11, 2007 Search Report dated Aug. 28, 2008.
PCT/US2007/011456 filed May 11, 2007 Written Opinion dated Aug. 28, 2008.
PCT/US2008/010520 dated Sep. 8, 2008 Search Report dated Feb. 24, 2009.
PCT/US2008/010520 filed Sep. 8, 2008 Written Opinion dated Feb. 24, 2009.
PCT/US2008/067679 filed Jun. 20, 2008 Search Report dated Sep. 30, 2008.
PCT/US2008/067679 filed Jun. 20, 2008 Written Opinion mailed on Sep. 30, 2008.
PCT/US2008/070330 filed Jul. 17, 2008 Search Report dated Dec. 1, 2008.
PCT/US2008/070330 filed Jul. 17, 2008 Written Opinion dated Dec. 1, 2008.
PCT/US2008/070345 filed Jul. 17, 2008 Search Report mailed on Dec. 1, 2008.
PCT/US2008/070345 filed Jul. 17, 2008 Written Opinion dated Dec. 1, 2008.
PCT/US2008/078976 filed Apr. 2, 2009 Search Report and Written Opinion dated Apr. 3, 2009.
PCT/US2009/062854 filed Oct. 30, 2009 International Preliminary Report on Patentability dated May 5, 2011.
PCT/US2009/062854 filed Oct. 30, 2009 International Search Report dated Dec. 10, 2009.
PCT/US2009/062854 filed Oct. 30, 2009 Search Report dated Dec. 23, 2009.
PCT/US2009/062854 filed Oct. 30, 2009 Written Opinion dated Dec. 10, 2009.
PCT/US2009/062854 filed Oct. 30, 2009 Written Opinion dated Dec. 23, 2009.
PCT/US2010/030256 filed Apr. 7, 2010 Search Report and Written Opinion dated Jun. 4, 2010.
PCT/US2010/030256 filed Apr. 7, 2010 Search Report dated Jun. 4, 2010.
U.S. Appl. No. 12/796,133, filed Jun. 8, 2010 Non-Final Office Action dated Feb. 17, 2011.
U.S. Appl. No. 12/796,133, filed Jun. 8, 2010 Notice of Allowance dated Jun. 9, 2011.
U.S. Appl. No. 12/419,854, filed Apr. 7, 2009 Non-Final Office Action dated Aug. 5, 2011.
U.S. Appl. No. 13/113,834, filed May 23, 2011 Non-Final Office Action dated Jul. 17, 2012.
U.S. Appl. No. 29/239,163, filed Sep. 27, 2005 entitled Injectable Power Port, listing Eddie K. Burnside as inventor.
U.S. Appl. No. 29/247,954, filed Jul. 21, 2006 entitled Injectable Power Port, listing Eddie K. Burnside as inventor.
U.S. Appl. No. 29/247,954, filed Jul. 21, 2006 Non-Final Office Action dated Apr. 6, 2007.
U.S. Appl. No. 29/247,954, filed Jul. 21, 2006 Notice of Allowability dated Jul. 30, 2007.
U.S. Appl. No. 29/284,454, filed Sep. 7, 2007 titled Implantable Port Device, listing John A. Zawacki and Annmarie Boswell as inventors, in which a Continued Prosecution Application was filed on Jan. 30, 2008.
U.S. Appl. No. 29/284,456, filed Sep. 7, 2007, titled Implantable Port Device, listing John A. Zawacki and Annemarie Boswell as inventors.
Vergara, et al., “Adverse Reactions to Contrast Medica in CT: Effects of Temperature and Ionic Property.” Radiology, vol. 199, No. 2, May 1996.
Vogelzang, Robert L., “Power Injection Through Central Venous Catheters: Physiological and Hemodynamic Considerations.” The McGaw Medical Center of Northwestern University, Feinberg School of Medicine. Jun. 23, 2004.
Wells, S. “Venous Access in Oncology and Haematology Patients: Part One.” Nursing Standard, vol. 22, No. 52, pp. 39-46, Sep. 3, 2008.
Wikipedia, “Port Catheter”, Dec. 15, 2011.
Williamson, et al., “Assessing the Adequacy of Peripherally Inserted Central Catheters for Power Injection of Intravenous Contrast Agents for CT.” Journal of Computer Assisted Tomography, vol. 6, No. 6, pp. 932-937, 2001.
U.S. Appl. No. 13/159,230, filed Jun. 13, 2011 Notice of Allowance dated Aug. 1, 2012.
U.S. Appl. No. 13/250,909, filed Sep. 30, 2011 Notice of Allowance dated Aug. 6, 2012.
U.S. Appl. No. 11/368,954, filed Mar. 6, 2006 Final Office Action dated Jan. 27, 2010.
U.S. Appl. No. 11/368,954, filed Mar. 6, 2006 Supplemental Non-final Office Action mailed Oct. 2, 2009.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Final Office Action dated Aug. 13, 2010.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Final Office Action dated Oct. 20, 2011.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Final Office Action dated Sep. 21, 2009.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Non-Final Office Action dated Apr. 26, 2010.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Non-Final Office Action dated Apr. 7, 2011.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Non-Final Office Action dated Jan. 16, 2009.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Non-Final Office Action dated Oct. 28, 2010.
U.S. Appl. No. 11/380,621, filed Apr. 27, 2006 Final Office Action dated Jan. 14, 2010.
U.S. Appl. No. 11/380,621, filed Apr. 27, 2006 Final Office Action dated Jan. 23, 2009.
U.S. Appl. No. 11/380,621, filed Apr. 27, 2006 Final Office Action dated Mar. 8, 2011.
U.S. Appl. No. 11/380,621, filed Apr. 27, 2006 Non-Final Office Action dated Jul. 1, 2009.
U.S. Appl. No. 11/380,621, filed Apr. 27, 2006 Non-Final Office Action dated Jun. 6, 2008.
U.S. Appl. No. 11/725,287, filed Mar. 19, 2007 Non-final Office Action issued on Dec. 3, 2008.
U.S. Appl. No. 11/725,287, filed Mar. 19, 2007 Non-final Office Action issued on Jun. 12, 2009.
U.S. Appl. No. 11/725,287, filed Mar. 19, 2007 Non-final Office Action issued on Mar. 29, 2010.
U.S. Appl. No. 11/937,302, filed Nov. 8, 2007 Final Office Action dated Oct. 13, 2011.
U.S. Appl. No. 11/937,302, filed Nov. 8, 2007 Non-Final Office Action dated Jun. 18, 2012.
U.S. Appl. No. 11/937,302, filed Nov. 8, 2007 Final Office Action dated Feb. 11, 2011.
U.S. Appl. No. 11/937,302, filed Nov. 8, 2007 Non-Final Office Action dated Apr. 15, 2011.
U.S. Appl. No. 11/937,302, filed Nov. 8, 2007 Non-Final Office Action dated Sep. 13, 2010.
U.S. Appl. No. 12/023,280, filed Jan. 31, 2008 Final Office Action dated Mar. 9, 2010.
U.S. Appl. No. 12/023,280, filed Jan. 31, 2008 Non-Final Office Action dated Dec. 13, 2010.
U.S. Appl. No. 12/023,280, filed Jan. 31, 2008 Non-Final Office Action dated Jul. 23, 2009.
U.S. Appl. No. 12/023,280, filed Jan. 31, 2008 Non-Final Office Action dated Oct. 5, 2009.
U.S. Appl. No. 12/023,280, filed Jan. 31, 2008 Notice of Allowance dated Mar. 28, 2011.
U.S. Appl. No. 12/143,377, filed Jun. 20, 2008 Final Office Action mailed Oct. 19, 2009.
U.S. Appl. No. 12/143,377, filed Jun. 20, 2008 Non-final Office Action mailed Apr. 27, 2009.
U.S. Appl. No. 12/175,182, filed Jul. 17, 2008 Non-final Office Action mailed Sep. 3, 2009.
U.S. Appl. No. 12/267,160, filed Nov. 7, 2008 Final Office Action dated Jun. 1, 2012.
U.S. Appl. No. 12/267,160, filed Nov. 7, 2008 Non-Final Office Action dated Nov. 1, 2011.
U.S. Appl. No. 12/419,854, filed Apr. 7, 2009 Final Office Action dated Nov. 29, 2011.
U.S. Appl. No. 12/419,854, filed Apr. 7, 2009 Non-Final Office Action dated Jun. 26, 2012.
U.S. Appl. No. 12/419,957, filed Apr. 7, 2009 Advisory Action dated Feb. 18, 2011.
U.S. Appl. No. 12/419,957, filed Apr. 7, 2009 Final Office Action dated Dec. 7, 2010.
U.S. Appl. No. 12/419,957, filed Apr. 7, 2009 Non-Final Office Action dated Feb. 18, 2010.
U.S. Appl. No. 12/419,957, filed Apr. 7, 2009 Non-Final Office Action dated Jul. 29, 2010.
U.S. Appl. No. 12/419,957, filed Apr. 7, 2009 Non-Final Office Action dated Jun. 30, 2009.
U.S. Appl. No. 12/419,957, filed Apr. 7, 2009 Notice of Allowance dated Mar. 7, 2011.
U.S. Appl. No. 12/420,007, filed Apr. 7, 2009 Final Office Action dated Feb. 18, 2010.
U.S. Appl. No. 12/420,007, filed Apr. 7, 2009 Non-Final Office Action dated Jul. 14, 2009.
U.S. Appl. No. 12/420,028, filed Apr. 7, 2009 Non-Final Office Action dated Jan. 5, 2011.
U.S. Appl. No. 12/420,028, filed Apr. 7, 2009 Notice of Allowance dated Apr. 1, 2011.
U.S. Appl. No. 12/617,981, filed Nov. 13, 2009 Advisory Action dated Sep. 15, 2011.
U.S. Appl. No. 12/617,981, filed Nov. 13, 2009 Final Office Action dated Aug. 2, 2012.
U.S. Appl. No. 12/617,981, filed Nov. 13, 2009 Final Office Action dated Jun. 21, 2011.
U.S. Appl. No. 12/617,981, filed Nov. 13, 2009 Non-Final Office Action dated Dec. 21, 2011.
U.S. Appl. No. 12/617,981, filed Nov. 13, 2009 Non-Final Office Action dated Jan. 5, 2011.
CN 201080020088.3 filed Nov. 7, 2011 First Office Action dated Mar. 4, 2013.
ECRI Institute, Healthcare Product Comparison System, Dec. 2007.
EP 06751664.1 filed Apr. 27, 2006 First Examination Report dated Jul. 11, 2013.
EP 06845998.1 filed Dec. 21, 2006 Examination Report dated May 13, 2013.
EP 10183380.4 filed Apr. 25, 2006 European Search Report dated May 22, 2013.
EP 10183382.0 filed Apr. 25, 2006 European Search Report dated May 22, 2013.
EP 10183394.5 filed Apr. 25, 2006 European Search Report dated May 22, 2013.
EP 10183398.6 filed Apr. 25, 2006 European Search Report dated May 22, 2013.
EP 10762377.9 filed Oct. 5, 2011 Office Action dated Jul. 17, 2013.
EP 13158343.7 filed Mar. 8, 2013 Extended European Search Report dated May 14, 2013.
Ethanol Lock Technique for Prevention and Treatment of Central line-Associated Bloodstream Infections (NEBRASKA) Aug. 13, 2011, Accessed: Jun. 29, 2013 http://www.nebraskamed.com/app—files/pdf/careers/education-programs/asp/tnmc—etohlock—final.pdf.
JP 2012-156976 filed Jul. 12, 2012 Submission of Documents by Third Party dated May 14, 2013.
Medcomp Dialysis and Vascular Access Products (MEDCOMP) Jun. 30, 2009, Accessed Jun. 29, 2013 http://www.medcompnet.com/products/flipbook/pdf/PN2114G—Medcomp—Catalog.pdf.
PCT/US2013/031035 filed Mar. 13, 2013 International Search Report and Written Opinion dated Jun. 3, 2013.
Takeuchi, Syuhei et al., “Safety Considerations in the Power Injection of Contrast Medium via a Totally Implantable Central Venous Access System,” Japan Journal of Interventional Radiology vol. 20, No. 1, pp. 27-30, Jan. 2005.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Notice of Allowance dated Apr. 29, 2013.
U.S. Appl. No. 12/419,854, filed Apr. 7, 2009 Advisory Action dated May 17, 2013.
U.S. Appl. No. 12/419,854, filed Apr. 7, 2009 Final Office Action dated Feb. 14, 2013.
U.S. Appl. No. 12/420,007, filed Apr. 7, 2009 Final Office Action dated Mar. 22, 2013.
U.S. Appl. No. 12/917,323, filed Nov. 1, 2010 Advisory Action dated Apr. 10, 2013.
U.S. Appl. No. 13/438,586, filed Apr. 3, 2012 Advisory Action dated May 29, 2013.
U.S. Appl. No. 13/438,586, filed Apr. 3, 2012 Final Office Action dated Mar. 7, 2013.
U.S. Appl. No. 13/471,219, filed May 14, 2012 Non-Final Office Action dated Jul. 10, 2013.
U.S. Appl. No. 13/571,088, filed Aug. 9, 2012 Final Office Action dated Jul. 16, 2013.
U.S. Appl. No. 13/571,088, filed Aug. 9, 2012 Non-Final Office Action dated Feb. 27, 2013.
U.S. Appl. No. 13/776,451, filed Feb. 25, 2013 Non-Final Office Action dated Jul. 24, 2013.
U.S. Appl. No. 13/853,942, filed Mar. 29, 2013 Non-Final Office Action dated Jul. 26, 2013.
U.S. Appl. No. 95/002,089, filed Aug. 20, 2012 Action Closing Prosecution dated Jun. 12, 2013.
U.S. Appl. No. 95/002,090, filed Aug. 20, 2012 Action Closing Prosecution dated Jun. 12, 2013.
U.S. Appl. No. 95/002,092, filed Aug. 20, 2012 Action Closing Prosecution dated Jun. 12, 2013.
Allergan, Inc. LAP-BAND® System Fact Sheet. © 2007.
AngioDynamics, Smart Port Guidelines for Health Care Providers, 1996.
B. Braun, Easypump Product Page, accessed May 11, 2011.
B. Braun, Port Catheter Systems Product Page, accessed May 11, 2011.
BARD Access Systems Mar. 21, 1995 Product Release to Market form for “M.R.I. Port with 8 Fr. ChronoFlexO Catheter”, “M.R.I. Port with 8Fr. ChronoFlex Catheter with Intro-Eze™”, “M.R.I. Port with 8. Fr ChronoFlex Catheter and Peel Apart”, “M.R.I. Port with 8Fr. ChronoFlex Catheter Demo Kit”. Drawings included.
Bard Healthcare Leaflet (2001).
Baxter Guidelines on Port Maintainence (Jun. 2003).
Baxter Healthport® Focus (Oct. 1999).
Baxter Healthport® Venous Systems (Oct. 2002).
Baxter Patient Information, Healthport® System (May 1999).
Baxter Therapy Systems, Baxter Healthport® Jan. 1999.
Biffi, R. et al. “Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients.” Annals of Oncology 15:296-300, 2004.
Biffi, R., et al. “Best Choice of Central Venous Insertion Site for the Prevention of Catheter-Related Complications in Adult Patients Who Need Cancer Therapy: A Randomized Trial.” Annals of Oncology, Jan. 29, 2009.
Biffi, Roberto, et al. “A Randomized, Prospective Trial of Central Venous Ports Connected to Standard Open-Ended or Groshong Catheters in Adult Oncology Patients.” American Cancer Society, vol. 92, No. 5, pp. 1204-1212, Sep. 1, 2001.
BioEnterics Corporation, LAP-BAND® “Adjustable Gastric Banding System” Product Brochure.
Braun Product Catalog (Aug. 2005).
Cardiovascular and Interventional Radiology, Review Article, “Central Venous Access Catheters: Radiological Management of Complications,” by U.K. Teichgraber, B. Gebauer, T. Benter, H.J. Wagner, published online Jul. 31, 2003.
Carlson et al., “Safety Considerations in the Power Injection of Contrast Media Via Central Venous Catheters during Computed Tomographic Examinations,” Investigative Radiology, (May 1992) 27: 337-340.
Clinical Plastic Products, “Oncology Jet Port Plus Catheter Systems” Instructions for Use, 2011.
Cook Vital-Port® Product Catalog (2000).
Costa, Nancy, “More Than Skin Deep: An Overview of Iodinated Contrast Media . . . ” Journal for the Association for Vascular Access, vol. 8, No. 4, 2003.
Costa, Nancy, “Understanding Contrast Media.” Journal of Infusion Nursing, vol. 27, No. 5, Sep./Oct. 2004.
Coyle, Douglas et al, Power Injection of Contrast Media via Peripherally Inserted Central Catheters for CT, J Vasc Interv Radiol, pp. 809-814, vol. 15, 2004.
Deltec Port Systems (Feb. and Apr. 1996).
Department of Health and Human Services, C-Port 510(k) FDA Clearance, Jun. 5, 2003.
EP 06751411 filed Apr. 25, 2006 Office Action dated Aug. 10, 2009.
EP 06751411 filed Apr. 25, 2006 Office Action dated Sep. 2, 2008.
EP 06751411 filed Apr. 25, 2006 Opposition by Aesculap AG dated Oct. 5, 2011.
EP 06751411 filed Apr. 25, 2006 Opposition by Fresenius Kabi Deutschland GmbH dated Oct. 11, 2011.
EP 06751411 filed Apr. 25, 2006 Opposition by pfm medical ag dated Oct. 12, 2011.
EP 06845998 filed Dec. 21, 2006 Office Action dated Mar. 10, 2011.
EP 06845998 filed Dec. 21, 2006 Supplementary Search Report dated Jul. 22, 2010.
EP 99964086 filed Dec. 3, 1999 Office Action dated Dec. 15, 2005.
EP 99964086 filed Dec. 3, 1999 Office Action dated Mar. 1, 2005.
EP 99964086 filed Dec. 3, 1999 Office Action dated Mar. 30, 2005.
Extravasation of Radiologic Contrast, PA-PSRS Patient Safety Advisory, vol. 1 No. 3, Sep. 2004.
Extreme Access™ Bard Access Systems, Inc. Product Brochure, 2003.
Fallscheer, et al., “Injury to the Upper Extremity Cuased by Extravasation of Contrast Medium: A True Emergency.” Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, vol. 41, pp. 26-32, 2007.
Fresenius Brochure on Intraport 1, Intraport II, and Bioport (Nov. 1998).
Gebauer, B. et al., “Contrast Media Power Injection Using Central Venous Port Catheters—Results of an In-Vitro Study,” Experimental Radiology 2005: 177: 1417-1423.
Hou, Shaw-Min et al. “Comparisons of Outcomes and Survivals for Two Central Venous Access Port Systems.” Journal of Surgical Oncology, 91:61-66, 2005.
Inamed Health, BioEnterics® LAP-BAND® “Adjustable Gastric Banding System” Product Brochure, Dec. 2003.
Johnson, Kathleen A., “Power Injectable Portal Systems.” Journal of Radiology Nursing, vol. 28, Issue 1, Mar. 2009.
JP 2007-558331 filed Mar. 6, 2006 Office Action dated May 17, 2011.
JP 2008-509056 filed Apr. 25, 2006 Office Action dated Apr. 4, 2012.
JP 2008-509056 filed Apr. 25, 2006 Office Action dated Jun. 7, 2011.
Kaste et al., “Safe use of power injectors with central and peripheral venous access devices for pediatric CT,” Pediatr Radiol (1996) 26: 499-501.
L-CATH® FOR PORTS, Luther Medical Products, Inc., Tustin, California, 2 pages, 1994.
LaMaitre Vascular “Port Implantations: using the OptiLock Implantable Port,” product information, available at http://www.lemaitre. com/specs.pop.asp, last accessed Apr. 2003, 14 pages.
LAP-BAND AP™ “System with Adjustable Gastric Banding system with OMNIFORM TN Design,” Product Brochure, Jul. 2007, 16 pages.
Bard Access Systems, BardPort and X-Port Implanted Ports Brochure, © 2007.
Bard Access Systems, BardPort, Slim Port and X-Port Instructions for Use, May 2003.
Bard Access Systems, BardPort™ Implanted Ports Patient Information, Feb. 1993.
Bard Access Systems, Ports Brochure, © 2003.
Bard Access Systems, Titanium Dome Implantable Port, http://www.bardacess.com, last accessed Jan. 10, 2012.
CN 200980153471.3 filed Jun. 30, 2011 First Office Action dated Dec. 25, 2012.
EP 06751411 filed Apr. 25, 2006 Decision Revoking the European Patent dated Aug. 1, 2012.
EP 06845998.1 filed Dec. 21, 2006 Examination Report dated Nov. 7, 2012.
EP 10762377.9 filed Oct. 5, 2011 European Search Report dated Aug. 3, 2012.
JP 2007-558331 filed Mar. 6, 2006 Office Action dated Jan. 22, 2013.
Medtronic IsoMed® Constant-Flow Infusion System: Clinical Reference Guide for Hepatic Arterial Infusion Therapy, Revised Sep. 2000.
Nucleus Cochlear Implant Systems; User Manual for the ESPrit and ESPrit 22 speech processor and accessories, Issue 3, Apr. 2000.
PCT/US11/37038 filed May 18, 2011 Written Opinion and Search Report dated Aug. 30, 2011.
PCT/US2011/037038 filed May 18, 2011 International Preliminary Report on Patentability dated Nov. 29, 2012.
PCT/US2011/037038 filed May 18, 2011 International Search Report and Written Opinion dated Aug. 30, 2011.
Request for Inter partes Reexamination of U.S. Patent No. 7,785,302, filed Aug. 20, 2012.
Request for Inter partes Reexamination of U.S. Patent No. 7,947,022, filed Aug. 20, 2012.
Request for Inter partes Reexamination of U.S. Patent No. 7,959,615, filed Aug. 20, 2012.
U.S. Appl. No. 11/937,302, filed Nov. 8, 2007 Final Office Action dated Nov. 8, 2012.
U.S. Appl. No. 12/267,160, filed Nov. 7, 2008 Examiner's Answer dated Dec. 5, 2012.
U.S. Appl. No. 12/420,007, filed Apr. 7, 2009 Non-Final Office Action dated Oct. 16, 2012.
U.S. Appl No. 12/917,323, filed Nov. 1, 2010 Final Office Action dated Jan. 29, 2013.
U.S. Appl. No. 12/917,323, filed Nov. 1, 2010 Non-Final Office Action dated Aug. 15, 2012.
U.S. Appl. No. 13/113,834, filed May 23, 2011 Final Office Action dated Nov. 23, 2012.
U.S. Appl. No. 13/438,586, filed Apr. 3, 2012 Non-Final Office Action dated Sep. 19, 2012.
U.S. Appl. No. 29/382,235, filed Dec. 30, 2010 Non-Final Office Action dated Oct. 3, 2012.
U.S. Appl. No. 29/382,246, filed Dec. 30, 2010 Notice of Allowance dated Oct. 3, 2012.
U.S. Appl. No. 95/002,089, filed Aug. 20, 2012 Office Action In and Order Granting/Denying Request for Inter Partes Reexamination dated Nov. 7, 2012.
U.S. Appl. No. 95/002,090, filed Aug. 20, 2012 Office Action In and Order Granting/Denying Request for Inter Partes Reexamination dated Nov. 7, 2012.
U.S. Appl. No. 95/002,092, filed Aug. 20, 2012 Office Action In and Order Granting/Denying Request for Inter Partes Reexamination dated Nov. 13, 2012.
PCT/US2010/030256 filed Apr. 7, 2010 Written Opinion dated Jun. 4, 2010.
PCT/US2010/054994 filed Nov. 1, 2010 Search Report dated Jan. 10, 2011.
PCT/US2010/054994 filed Nov. 1, 2010 Written Opinion dated Jan. 10, 2011.
Port-A-Cath® P.A.S. PORT® Systems by Deltec, Product Specifications, 1999.
PORT-A-CATH® “Implantable Epidural, Aterial and Peritonial Access Systems” Internet Product Listing. <<http://web.archive.org/web/20001119035900/www.deltec.com/cPacspl.htm.>> last accessed Jun. 4, 2012.
PORT-A-CATH® “Many PORT-A-CATH® System Choices” Product Brochure. © 1996 SIMS Deltec, Inc.
PORT-A-CATH® & PORT-A-CATH® II Dual-lumen Implantable Venous Access Systems Product Specifications, 2005.
PORT-A-CATH® and P.A.S. PORT® POWER P.A.C. Information Sheet, 2006.
Rappolt, Richard T., et al. “Radiopaque Codification and X-ray Identification of Ingested Drugs.” Ingestive Radiology, May-Jun. 1966.
Salis et al., “Maximal flow rates possible during power injection through currently available PICCs: An in-vitro study,” J Vasc Interv Radiol 2004; 15:275-281.
Sandstede, Joern, “Pediatric CT,” available online at www.multislice-ct.com, MultiSLICE-CT.com, version 02, May 2, 2003.
Sanelli, et al., “Safety and Feasibility of Using a Central Venous Catheter for Rapid Contrast Injection Rates.” American Journal of Radiology, vol. 183, pp. 1829-1834, Dec. 2004.
Shah, Tilak M., “Radiopaque Polymer Formulations for Medical Devices.” Medical Device and Diagnostic Industry, Mar. 2000.
Smith Medical, PORT-A-CATH® “Single-lumen Implantable Vascular Access Systems” Product Specifications, 2004.
Smith, Lisa Hartkoph, “Implanted Ports, Computed Tomography, Power Injectors, and Catheter Rupture.” Clinical Journal of Oncology Nursing, vol. 12 , No. 5. Oct. 2008.
Smiths Medical, “Smiths Medical Launches Implantable Ports for Easy Viewing Under CT Scans” Press Release, Jan. 5, 2011.
Soloman, et al., “CIN Strategies: Anticipate, Manage, Prevent.” Supplement to Imaging Economics, May 2007.
Statement of Prof. Dr. med. Karl R. Aigner, Oct. 11, 2011.
Steinbach, Barbara G. , Hardt, N. Sisson, Abbitt, Patricia L., Lanier, Linda, Caffee, H. Hollis, “Breast Implants, Common Complications, and Concurrent Breast Disease.” RadioGraphics, vol. 13, No. 1, pp. 95-118, 1993.
Sullivan et al. “Radiopaque Markers on Mammary Implants.” American Journal of Roentgenology 153(2):428, Aug. 1989.
U.S. Food and Drug Administration, “Guidance for Institutional Review Boards and Clinical Investigators 1998 Update: Medical Devices.” Version Sep. 10, 2008.
U.S. Appl. No. 60/658,518, filed Mar. 4, 2005, publicly accessible Oct. 5, 2006.
Urquiola, Javier, et al., “Using Lead Foil as a Radiopaque Marker for Computerized Tomography Imaging When Implant Treatment Planning.” The Journal of Prosthetic Dentistry, 1997.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Office Action dated Aug. 28, 2007.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Advisory Action dated Jan. 23, 2007.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Non-Final Office Action dated Feb. 13, 2006.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Non-Final Office Action dated May 20, 2009.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Non-final Office Action mailed Mar. 20, 2008.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Office Action dated Feb. 28, 2007.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Office Action dated Jul. 28, 2006.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Office Action mailed Sep. 30, 2008.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Non-Final Office Action dated May 12, 2006.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated Dec. 28, 2006.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated Jun. 20, 2008.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated Mar. 30, 2009.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated May 28, 2007.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated Nov. 28, 2006.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated Oct. 31, 2007.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated Sep. 21, 2009.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Advisory Action dated Dec. 1, 2011.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Notice of Allowance dated Jan. 6, 2012.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Final Office Action dated Aug. 3, 2011.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Final Office Action dated Jun. 19, 2009.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Final Office Action dated Jun. 22, 2010.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Non-Final Office Action dated Feb. 13, 2008.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Non-Final Office Action dated Jan. 21, 2010.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Non-Final Office Action dated Mar. 16, 2011.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Non-Final Office Action dated Sep. 18, 2008.
U.S. Appl. No. 11/368,954, filed Mar. 6, 2006 Non-Final Office Action dated Jul. 21, 2009.
U.S. Appl. No. 11/368,954, filed Mar. 6, 2006 Notice of Allowance dated Jun. 24, 2010.
CN 200980153471.3 filed Jun. 30, 2011 Second Office Action dated Sep. 18, 2013.
EP 06751411 filed Apr. 25, 2006 Decision of the Technical Board of Appeal dated Jul. 24, 2013.
JP 2007-558331 filed Mar. 6, 2006 Office Action dated Aug. 20, 2013.
JP 2012-156976 filed Jul. 12, 2012 Notice of Reasons for Refusal dated Aug. 27, 2013.
MX/a/2011/004499 filed Apr. 28, 2011 First Office Action dated Jul. 25, 2013.
U.S. Appl. No. 13/438,586, filed Apr. 3, 2012 Notice of Allowance dated Sep. 16, 2013.
U.S. Appl. No. 13/776,517, filed Feb. 25, 2013 Non-Final Office Action dated Nov. 15, 2013.
Bard Access Systems, BadPort, SlimPort, X-Port Instructions for Use, 24 pages, Oct. 2012.
Bard Access Systems, PowerPort and PowerLoc CT Guide, 11 pages, Dec. 2009.
Bard Access Systems, PowerPort and PowerLoc Product Brochure, 6 pages, © 2007.
Bard Access Systems, PowerPort CT Guide, 16 pages, Mar. 2007.
Bard Access Systems, PowerPort Guidelines for CT Technologists, 1 page, Feb. 2007.
Bard Access Systems, PowerPort Guidelines for CT Technologists, 1 page, Jul. 2006.
Bard Access Systems, PowerPort Guidelines for Nurses, 1 page, Feb. 2007.
Bard Access Systems, PowerPort Guidelines for Physicians, 1 page, Feb. 2007.
Bard Access Systems, PowerPort Prescription Pad, 1 page, © 2007.
Bard Access Systems, PowerPort™ Implantable Port Product Information, © 2007.
Bard Access Systems, When in Doubt, SCOUT!, 1 page, © 2007.
Biotronik, Stratos Cardiac Resynchronization Therapy Pacemakers Technical Manual, 179 pages, © 2008.
Boston Scientific, Xcela™ Power Injectable PICC Directions for Use, 12 pages, © 2007.
CN 200980153471.3 filed Jun. 30, 2011 Third Office Action dated May 28, 2014.
CN 201080020088.3 filed Nov. 7, 2011 Second Office Action dated Nov. 21, 2013.
CN 201080051911.7 filed May 16, 2012 First Office Action dated Dec. 27, 2013.
CN 201080051911.7 filed May 16, 2012 Second Office Action dated Jul. 16, 2014.
EP 06845998.1 filed Dec. 21, 2006 Summons for Oral Proceedings dated Sep. 30, 2014.
EP 10 831 973.2 filed May 30, 2012 Extended European Search Report dated Jul. 4, 2014.
EP 10183394.5 filed Apr. 25, 2006 Opposition by Smiths Medical ASD, Inc. dated Apr. 25, 2014.
EP 13158343.7 filed Mar. 8, 2013 Summons to Attend Oral Proceedings dated Oct. 20, 2014.
JP 2012-156976 filed Jul. 12, 2012 Notice of Reasons for Refusal dated Apr. 8, 2014.
JP 2012-504826 filed Oct. 6, 2011 First Office Action dated Mar. 4, 2014.
JP 2013-209156 filed Oct. 4, 2013 Non-Final Office Action dated Oct. 7, 2014.
MX/a/2011/004499 filed Apr. 28, 2011 Second Office Action dated May 25, 2014.
PFM Medical, Xcela™ Power Injectable Port Directions for Use, 15 pages, © 2008.
STD Manufacturing, Brochure with a Hickman port, 1 page, date unknown.
U.S. Appl. No. 12/419,854, filed Apr. 7, 2009 Notice of Allowance dated Apr. 7, 2014.
U.S. Appl. No. 12/917,323, filed Nov. 1, 2010 Non-Final Office Action dated Aug. 26, 2014.
U.S. Appl. No. 13/110,734, filed May 18, 2011 Non-Final Office Action dated Jul. 7, 2014.
U.S. Appl. No. 13/776,517, filed Feb. 25, 2013 Final Office Action dated Jun. 30, 2014.
U.S. Appl. No. 13/776,517, filed Feb. 25, 2013 Notice of Allowance dated Sep. 23, 2014.
U.S. Appl. No. 13/853,956, filed Mar. 29, 2013 Non-Final Office Action dated Dec. 3, 2013.
U.S. Appl. No. 13/853,956, filed Mar. 29, 2013 Non-Final Office Action dated Sep. 15, 2014.
U.S. Appl. No. 13/853,961, filed Mar. 29, 2013 Non-Final Office Action dated Dec. 3, 2013.
U.S. Appl. No. 13/853,961, filed Mar. 29, 2013 Non-Final Office Action dated Sep. 12, 2014.
EP 06845998.1 filed Dec. 21, 2006 Examination Report dated Feb. 6, 2014.
EP 10183382.0 filed Apr. 25, 2006 Intent to Grant dated Mar. 7, 2014.
EP 11784194.0 filed Nov. 29, 2012 extended European search report dated Feb. 21, 2014.
EP 13158343.7 filed Mar. 8, 2013 Examination Report dated Feb. 4, 2014.
PCT/US2013/056019 filed Aug. 21, 2013 International Search Report and Written Opinion dated Feb. 28, 2014.
U.S. Appl. No. 13/776,517, filed Feb. 25, 2013 Non-Final Office Action dated Feb. 27, 2014.

Related Publications (1)

	Number	Date	Country
	20120259296 A1	Oct 2012	US

Provisional Applications (2)

	Number	Date	Country
	60658518	Mar 2005	US
	61110507	Oct 2008	US

Divisions (1)

	Number	Date	Country
Parent	12610084	Oct 2009	US
Child	13524712		US

Continuation in Parts (2)

	Number	Date	Country
Parent	12420028	Apr 2009	US
Child	12610084		US
Parent	11368954	Mar 2006	US
Child	12420028		US

Systems and methods for identifying an access port

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Term Extension

Abstract